Allosteric regulators selectively prevent \( \text{Ca}^{2+} \)-feedback of \( \text{Ca}_V \) and \( \text{Na}_V \) channels

Jacqueline Niu\(^1\), Ivy E Dick\(^2\), Wanjun Yang\(^3\), Moradeke A Bamgboye\(^2\), David T Yue\(^1\), Gordon Tomaselli\(^3\), Takanari Inoue\(^4,5\)*, Manu Ben-Johny\(^6\)**

\(^1\)Department of Biomedical Engineering, Johns Hopkins University, Baltimore, United States; \(^2\)Department of Physiology, University of Maryland, Baltimore, United States; \(^3\)Department of Cardiology, Johns Hopkins University, Baltimore, United States; \(^4\)Department of Cell Biology, Johns Hopkins University, Baltimore, United States; \(^5\)Center for Cell Dynamics, Institute for Basic Biomedical Sciences, Johns Hopkins University, Baltimore, United States; \(^6\)Department of Physiology and Cellular Biophysics, College of Physicians and Surgeons, Columbia University, New York, United States

Abstract Calmodulin (CaM) serves as a pervasive regulatory subunit of \( \text{Ca}_V1 \), \( \text{Ca}_V2 \), and \( \text{Na}_V1 \) channels, exploiting a functionally conserved carboxy-tail element to afford dynamic \( \text{Ca}^{2+} \)-feedback of cellular excitability in neurons and cardiomyocytes. Yet this modularity counters functional adaptability, as global changes in ambient CaM indiscriminately alter its targets. Here, we demonstrate that two structurally unrelated proteins, SH3 and cysteine-rich domain (stac) and fibroblast growth factor homologous factors (fhf) selectively diminish \( \text{Ca}^{2+} \)/CaM-regulation of \( \text{Ca}_V1 \) and \( \text{Na}_V1 \) families, respectively. The two proteins operate on allosteric sites within upstream portions of respective channel carboxy-tails, distinct from the CaM-binding interface. Generalizing this mechanism, insertion of a short RxxK binding motif into \( \text{Ca}_V1.3 \) carboxy-tail confers synthetic switching of CaM regulation by Mona SH3 domain. Overall, our findings identify a general class of auxiliary proteins that modify \( \text{Ca}^{2+} \)/CaM signaling to individual targets allowing spatial and temporal orchestration of feedback, and outline strategies for engineering \( \text{Ca}^{2+} \)/CaM signaling to individual targets.

DOI: https://doi.org/10.7554/eLife.35222.001

Introduction Supporting vital biological functions, voltage-gated calcium (\( \text{Ca}_V1 \) and \( \text{Ca}_V2 \)) and sodium (\( \text{Na}_V1 \)) channels are tuned by the \( \text{Ca}^{2+} \)-binding protein, calmodulin (CaM) (Ben-Johny et al., 2015; Catterall et al., 2017; Saimi and Kung, 2002). \( \text{Na}_V1 \) supports action potential initiation and propagation (Hille, 2001), while \( \text{Ca}_V1/2 \) initiate muscle contraction, neurotransmission, and gene transcription (Berridge et al., 2000; Clapham, 2007; Maier and Bers, 2002). Despite divergent functions, these channel families share a conserved carboxy-tail element, termed \( \text{Ca}^{2+} \)-inactivating (CI) module, that harbors CaM. Functionally, the CI module confers dynamic \( \text{Ca}^{2+} \)-dependent regulation to \( \text{Ca}_V1 \), \( \text{Ca}_V2 \), and \( \text{Na}_V1 \) that manifests as either inactivation (CDI) or facilitation (CDF), negative and positive feedback, respectively (Ben-Johny et al., 2015; Minor and Findeisen, 2010). Yet, this modularity poses a challenge – mechanisms that tune \( \text{Ca}^{2+} \)/CaM-feedback must distinguish between structurally similar targets. Global inhibition of CaM indiscriminately alters many processes (Persechini and Stemmer, 2002). Given the abundance of CaM-regulated proteins, mechanisms that adjust CaM signaling to individual targets are crucial (Marshall et al., 2015; Saimi and Kung, 2002). Physiologically, \( \text{Ca}^{2+} \)-regulation of \( \text{Ca}_V1 \) is critical for cardiac electrical stability (Limpitikul et al., 2014; Mahajan et al., 2008), rhythmicity of oscillatory neurons (Chan et al., 2007;
Huang et al., 2012, and vesicle release at ribbon synapses (Joiner and Lee, 2015). Ca\(_{\text{v}}\)2 modulation contributes to short-term synaptic plasticity and spatial learning (Adams et al., 2010; Jackman and Regehr, 2017; Nanou et al., 2016), while Na\(_{\text{v}}\)1 modulation tunes excitability of skeletal and cardiac muscle (Pitt and Lee, 2016; Van Petegem et al., 2012). Consequently, aberrant channel regulation underlies numerous maladies including cardiac arrhythmias (Venetucci et al., 2012; Zimmer and Surber, 2008), neurological and neuropsychiatric disorders (Adams and Snutch, 2007; Stryiessnig et al., 2010; Zamponi, 2016), and skeletal myotonia (Cannon, 2015).

Src homology 3 (SH3) and cysteine-rich domain (C1) proteins (stac) have emerged as attractive candidates that modulate Ca\(_{\text{v}}\) gating and trafficking (Polster et al., 2015; Suzuki et al., 1996). Initially identified in association with congenital skeletal myopathies as a structural protein that abets Ca\(_{\text{v}}\)1.1 plasmalemmal trafficking (Horstick et al., 2013; Linsley et al., 2017c; Polster et al., 2015), stac also suppresses Ca\(_{\text{v}}\)1.2 CDI (Campiglio et al., 2018; Wong King Yuen et al., 2017). Even so, the specificity of stac in tuning Ca\(^{2+}\)-regulation of the broader Ca\(_{\text{v}}\)/Na\(_{\text{v}}\) family, the underlying elementary mechanisms, and molecular determinants remain to be fully elucidated (Wong King Yuen et al., 2017). Stac isoforms (stac1-3) share a common architecture containing a C1 and two SH3 domains fused via a linker, and exhibit tissue-specific expression (Suzuki et al., 1996). Stac1/2 are expressed throughout the brain (Nelson et al., 2013; Suzuki et al., 1996), the peripheral nervous system (Legha et al., 2010), the retina (Wilhelm et al., 2014), and the inner ear (Cai et al., 2015), while stac3 is limited to the skeletal muscle (Nelson et al., 2013). Resolving mechanisms by which stac modulates Ca\(_{\text{v}}\) may furnish long-sought physiological insights (Suzuki et al., 1996).

Evolutionarily distinct from stac, fibroblast growth factor (fgf) homologous factors (fgf1-4, fgf11-14) are unconventional fgf that lack a secretory signal and serve as intracellular regulators of Na\(_{\text{v}}\) gating and trafficking (Goldfarb, 2005; Pablo and Pitt, 2016). Curiously, fhf interacts with the Na\(_{\text{v}}\) CI module in close proximity to the CaM binding interface, suggesting interplay between these modulators (Wang et al., 2012; Wang et al., 2011b). Yet, functionally, fhf is thought to modulate only voltage-dependent fast inactivation (Goldfarb et al., 2007; Lou et al., 2005; Wang et al., 2011a), with changes in Ca\(^{2+}\)-regulation unknown. Fhf isoforms are differentially expressed in the brain (Smallwood et al., 1996; Yan et al., 2014), peripheral nervous system (Ornitz and Itoh, 2001), and cardiac (Wei et al., 2011) and skeletal muscle (Kramer et al., 2012). Genetic variation in fhf4 is linked to spinocerebellar ataxia 27 (Coebergh et al., 2014) and fhf1 to cardiac arrhythmias (Wei et al., 2011), hinting at their relevance for regulating neuronal and cardiac excitability.

By leveraging synergistic insights from Ca\(_{\text{v}}\) and Na\(_{\text{v}}\) channels, we demonstrate that stac selectively diminishes Ca\(^{2+}\)-regulation of Ca\(_{\text{v}}\)1. In-depth analysis shows that stac binds to a distinct channel interface from CaM and uses an allosteric mechanism to lock Ca\(_{\text{v}}\)1 into a high open probability (P\(_{\text{O}}\)) gating mode. We further localize a minimal motif that recapitulates stac modulation of Ca\(_{\text{v}}\)1 gating. Paralleling stac-effect on Ca\(_{\text{v}}\)1, fhf reduces CDI of Na\(_{\text{v}}\)1 with no effect on Ca\(_{\text{v}}\)1. In all, our findings point to a general class of auxiliary proteins that intercept CaM signaling to individual targets, allowing spatial and temporal orchestration of Ca\(^{2+}\)-feedback.

**Results**

**Stac selectively suppresses Ca\(^{2+}\)-feedback of Ca\(_{\text{v}}\)1 channels**

We sought to determine stac effect on Ca\(_{\text{v}}\)1, Ca\(_{\text{v}}\)2, and Na\(_{\text{v}}\)1 channels in heterologous systems. **Figure 1A** shows baseline effects of stac on Ca\(_{\text{v}}\)1,2 (Campiglio et al., 2018; Polster et al., 2015; Wong King Yuen et al., 2017). Devoid of stac, Ca\(_{\text{v}}\)1,2 exhibits CaM-meditated CDI manifesting as enhanced decay of Ca\(^{2+}\) (red) versus Ba\(^{2+}\) current (black) when elicited using a step depolarization (**Figure 1A**, middle subpanel). As Ba\(^{2+}\) binds CaM poorly (Linse and Forsén, 1995), Ba\(^{2+}\)-currents furnish a baseline measure of voltage-dependent inactivation (VDI) without CDI. Upon stac2 co-expression, CDI is diminished (**Figure 1A**, right subpanel). To quantify steady-state extent of inactivation, we measured the fraction of peak Ca\(^{2+}\) and Ba\(^{2+}\) current remaining after 300 ms depolarization, r\(_{\text{Ca}}\) and r\(_{\text{Ba}}\) (**Figure 1**—**figure supplement 1A). The strength of CDI is quantified as CDI\(_{300}\) = 1 – r\(_{\text{Ca}}\)/r\(_{\text{Ba}}\), the fractional Ca\(^{2+}\)-dependent component of inactivation. Thus quantified, the population data confirm a reduction in CDI of Ca\(_{\text{v}}\)1.2 with stac2 (p=3.6 \times 10^{-5}; **Figure 1B**). Further analysis shows that both stac1 and stac3 isoforms also diminish CDI (p=2.0 \times 10^{-5} and 7.1 \times 10^{-5}, respectively, **Figure 1B** and **Figure 1**—**figure supplement 1A). Similarly, Ca\(_{\text{v}}\)1.3 short variant (Ca\(_{\text{v}}\)1.3s), a
Figure 1. Stac specifically abolishes Ca$^{2+}$/CaM-regulation in Ca$\text{V}_{1}$ channels. (A) Stac2 diminishes CDI of Ca$\text{V}_{1.2}$. Left, cartoon schematic shows Ca$\text{V}_{1.2}$. Middle, exemplar current traces evoked in response to +10 mV voltage-step shows robust CDI (rose shaded area) evident as enhanced current decay with Ca$^{2+}$ (red) versus Ba$^{2+}$ (black) as the charge carrier. Right, stac2 abolishes CDI. Steady-state levels of inactivation are assessed as the fraction of peak current remaining following 300 ms depolarization ($r_{Ca}$ and $r_{Ba}$) and CDI = 1 – $r_{Ca}/r_{Ba}$. (B) Bar graph displays population data of CDI$_{300}$ for Ca$\text{V}_{1.2}$ in the absence and in the presence of stac1, stac2, or stac3. Dashed line shows baseline CDI in the absence of stac for comparison. Each bar, mean ± S.E.M. obtained from specified number of cells (n). (C–D) Stac isoforms suppress CDI of Ca$\text{V}_{1.3}$, the canonical short variant, as confirmed by both exemplar traces (C) and population data (D). Format as in (A) and (B). (E–F) Stac2 abolishes CDI of Ca$\text{V}_{1.4}$ assessed in response to +20 mV test pulse. Format as in (A) and (B). (G–H) Stac2 spares CDF of Ca$\text{V}_{2.1}$, as evaluated using a prepulse protocol. An isolated test pulse to 0 mV elicits Ca$^{2+}$ currents with biphasic activation.
close homolog of Ca$_{v}$1.2, exhibits strong baseline CDI that is reduced on co-expression of stac1, stac2, and stac3 (p<1 x 10^{-5}; Figure 1C–D and Figure 1—figure supplement 1B). Generalizing this phenomenon, stac2 also reduces CDI of Ca$_{v}$1.4$_{a,b}$ (p=3.2 x 10^{-5}; Figure 1E–F; Figure 1—figure supplement 1C) (Tan et al., 2012).

Encouraged by its pervasiveness, we considered whether stac alters Ca^{2+}-dependent modulation of Ca$_{v}$2 isoforms that are abundant in the central nervous system. For Ca$_{v}$2.1, CaM elaborates both CDF and CDI (DeMaria et al., 2001; Lee et al., 2000). However, the Ca^{2+}-sensitivity of CDI process is over 50-fold weaker than that of CDF, casting this negative feedback beyond physiological bounds (Lee et al., 2015). As such, we probed whether stac tunes CDF of Ca$_{v}$2.1 using a well-established prepulse protocol (DeMaria et al., 2001; Thomas and Lee, 2016). Figure 1G displays wildtype Ca$_{v}$2.1 currents in the absence of stac2. On presentation of an isolated test pulse to 0 mV, the activation of Ca^{2+} current follows a biphasic response (gray trace). Following a brief voltage prepulse, however, the ensuing test pulse yields enhanced Ca^{2+}-currents with monophasic activation reflecting CDF (red trace). Further quantification revealed no change in CDF of Ca$_{v}$2.1 following the addition of stac2 in both exemplar current recordings (Figure 1G) and population data (Figure 1H; Figure 1—figure supplement 1D). For Ca$_{v}$2.2, CaM-regulation manifests as a kinetically slow CDI (Figure 1I) (Liang et al., 2003), that persists despite stac co-expression (Figure 1I; Figure 1—figure supplement 1E). Here CDI is quantified by metric CDI$_{800}$ = 1 – r$_{Ca}$/r$_{Ba}$, measured following 800 ms of depolarization. Likewise, neuronal Ca$_{v}$2.3 also possesses robust CDI, which is spared with stac2 co-expression (Figure 1Figure 1K–L; Figure 1—figure supplement 1F).

Lastly, we tested whether stac suppresses Ca^{2+}-regulation of Na$_{v}$1, related to Ca$_{v}$1. Although all Na$_{v}$1 possess a CI module homologous to both Ca$_{v}$1 and Ca$_{v}$2 (Babitch, 1990), CDI that bears mechanistic similarity to Ca$_{v}$ has been identified only in Na$_{v}$1.4 (Ben-Johny et al., 2014). Unlike Ca$_{v}$, Na$_{v}$ channels do not convey Ca^{2+} influx that triggers Ca^{2+}-feedback. We used rapid photo-uncaging of Ca^{2+} to produce a step-like increase in intracellular [Ca^{2+}], whose magnitude is simultaneously monitored via fluorescent indicators. Figure 1M displays baseline Ca^{2+}-regulation of Na$_{v}$1.4. As CDI is kinetically slow in comparison to fast inactivation, we applied a train of step depolarizations evoked at 10 Hz to probe Ca^{2+}-dependent effects (Ben-Johny et al., 2014). Without Ca^{2+}-uncaging, peak Na$_{v}$1.4 currents remained steady (gray dots). In response to an -10 µM Ca^{2+} step, the peak Na$_{v}$ current declined rapidly revealing CDI (red envelope). Stac overexpression, however, does not disrupt Na$_{v}$1.4 CDI (Figure 1M–N; Figure 1—figure supplement 1G). Overall, these results show the specificity of stac in tuning Ca^{2+}-regulation of Ca$_{v}$1 channels.

**Stac interacts with Ca$_{v}$1 CI module to elicit CDI suppression**

We sought to identify molecular mechanisms that underlie selective Ca$_{v}$1 modulation by stac. As the stac effect here is inferred based on overexpression analysis, we determined relative concentration requirements for stac binding to Ca$_{v}$1 holo-channel complexes within the milieu of living cells. We used live cell FRET 2-hybrid assay (Erickson et al., 2001) to probe the interaction of CFP-tagged stac3 with YFP-linked Ca$_{v}$1.3S. As all three stac variants suppress the CDI of all Ca$_{v}$1 isoforms, we
chose CaV1.3 as YFP-tethered channels and a repertoire of YFP-tagged intracellular loop peptides are readily available for in-depth binding analysis (Yang et al., 2014). Stac3 was selected for its high potency in suppressing CaV1.3 CDI (Figure 1D). Accordingly, we quantified FRET efficiency (E_D) between FRET pairs co-expressed in individual cells. By leveraging stochastic expression of the FRET pairs in cells, we obtained a saturating Langmuir relationship between E_D and the free acceptor concentration (A_free), permitting estimation of relative binding affinities (K_D,EFF). Thus probed, we obtained a CaV1.3 holo-channel affinity for stac3 of K_D,EFF = 1458 ± 251 D_free units proportional to ~47 nM (Figure 2A). By comparison, similar analysis of CaM binding to CaV1.3 showed K_D,EFF = 700 D_free units ~ 22 nM (Yang et al., 2014). Consequently, stac’s relatively high binding-affinity for CaV1.3 suggests that it may be a potent modulator even at low concentrations.

With holo-channel binding assured, we systematically scanned YFP-tagged CaV1.3 intracellular domains (Yang et al., 2014) for stac binding sites (Figure 2B; Figure 2—figure supplement 1A). We found that stac3 binds well to the CI region (K_D,EFF = 20697 ± 3023 D_free ~ 0.67 ± 0.1 µM, Figure 2C). By contrast, analysis of the amino-terminus, intracellular loops between domains I and II

![Figure 2](https://example.com/figure2.png)

**Figure 2.** Stac interacts with the channel carboxy-terminus. (A) Live-cell FRET 2-hybrid assay shows high-affinity interaction between CFP-tagged stac3 with YFP-tethered holo-CaV1.3 channels in the presence of auxiliary β2A and α2δ subunits. (B) Cartoon shows FRET pairs, CFP-stac3 with YFP-CI, YFP-PCI, and YFP-IQ of CaV1.3. (C) FRET-binding curves show robust binding of stac3 to both the CI and PCI segment while binding to IQ is weaker. (D) Bar graph summarizes the relative association constant, K_D,EFF, of stac2 binding to major channel intracellular domains. (E–F) Transferring CaV1.3 CI to CaV2.3 (CaV2.3/1.3 CI) unveils latent stac2-mediated suppression of CDI. Format as in Figure 1A – B.

DOI: https://doi.org/10.7554/eLife.35222.004

The following figure supplement is available for figure 2:

Figure supplement 1. Systematic FRET 2-hybrid scan of major intracellular loops of CaV1.3 with stac.

DOI: https://doi.org/10.7554/eLife.35222.005
(I-II loop), domains II and III (II-III loop), and domains III and IV (III-IV loop) revealed far weaker binding (Figure 2D; Figure 2—figure supplement 1B–E). To further localize the putative binding loci, we subdivided the CI module into two: (1) a proximal CI segment (PCI) composed of dual vestigial EF hand and preIQ segments and (2) the IQ domain (IQ). The YFP-tagged PCI segment bound stac3 with approximately tenfold higher affinity ($K_{d,\text{EFF}} = 17725 \pm 3990$ $D_{\text{free}}=0.58 \pm 0.1$ $\mu$M) than the downstream IQ domain ($K_{d,\text{EFF}} = 204739 \pm 25465$ $D_{\text{free}}=6.67 \pm 0.8$ $\mu$M) (Figure 2C–D). In all, systematic FRET analysis reveals that stac binds to CaV1 CI relying on upstream elements including the dual vestigial EF hand and preIQ domains, an interface distinct from that for CaM (Bazzazi et al., 2013; Minor and Findeisen, 2010).

To test for functional relevance of stac binding to the CaV1 CI module, we sought to confer stac-sensitivity to a stac-insensitive channel via a chimeric approach. We turned to CaV2.3 that lacks strong stac-mediated CDI suppression, yet forms functional chimeras with CaV1 (Mori et al., 2008; Yang et al., 2014). We replaced the CI region of CaV2.3 with the corresponding segment from CaV1.3 (CaV2.3/1.3 CI). Devoid of stac, CaV2.3–1.3 CI channels exhibit CDI isolated by high intracellular buffering (Figure 2E–F; Figure 2—figure supplement 1F). In contrast to wildtype CaV2.3, stac2 co-expression attenuated CDI ($p=4.7 \times 10^{-4}$, Figure 2E–F; Figure 2—figure supplement 1F), suggesting that CaV1 CI module is necessary for stac-mediated CDI suppression.

**Stac uses an allosteric mechanism to suppresses CaM signaling**

Given that both CaM and stac share the CI module as an effector site, two disparate mechanistic possibilities may allow suppression of Ca$^{2+}$-regulation. First, stac may competitively displace Ca$^{2+}$-free CaM (apoCaM) from its preassociation site. Second, stac may supersede CaM signaling to the channel pore via an allosteric mechanism. Systematic FRET analysis suggests that stac preferentially binds upstream CI elements (Figure 2D) while high-affinity CaM preassociation is supported via the IQ domain (Bazzazi et al., 2013; Minor and Findeisen, 2010), hinting that the two modulatory proteins may bind concurrently. To rule out competitive displacement of CaM preassociation, we covalently tethered CaM onto the CaV1.3 carboxy-tail using a poly-glycine linker (CaV1.3$_C$-CaM) (Mori et al., 2004; Yang et al., 2014). This maneuver preserves CDI (Figure 3A left) and ensures a high local CaM concentration near CaV1 extending into the millimolar range, sufficient to protect the channel from a competitive inhibitor (Mori et al., 2004). Dominant-negative CaM$_{1234}$ with its Ca$^{2+}$-binding sites disabled, typically displaces intact apoCaM from the CI module thereby resulting in a loss of CDI for wildtype channels (Figure 3—figure supplement 1A–B) (Yang et al., 2014). CDI of CaV1.3$_C$-CaM persists despite CaM$_{1234}$ co-expression (gray bar, Figure 3B; Figure 3—figure supplement 1C–D). By contrast, CDI of CaV1.3$_C$-CaM is diminished by co-expression of stac2 ($p=3.8 \times 10^{-4}$, Figure 3A–B; Figure 3—figure supplement 1E) and stac3 ($p=4.5 \times 10^{-4}$, Figure 3—figure supplement 1F). As a further test, co-expression of untethered CaV1.3$_C$ with both CaM and stac2 also showed low CDI (Figure 3—figure supplement 1G). We observed a similar fate for CaV1.2-CaM with stac2 ($p=1.5 \times 10^{-5}$, Figure 3C–D; Figure 3—figure supplement 1H). These findings suggest that stac does not need to dislodge CaM from its CaV1.3 carboxy-tail binding interface to exert functional modulation.

To test this possibility, we undertook FRET 2-hybrid assay comparing binding of CFP-tagged CaM to YFP-tagged CaV1.3 CI in the presence and absence of unlabeled stac3. If stac3 were to competitively dislodge CaM, then this binding is predicted to be weakened. At baseline, CaM binds to CaV1.3 CI with a relative dissociation constant, $K_{d,\text{EFF}} \approx 4000$ $D_{\text{free}}$ units (Figure 3E) (Ben Johnny et al., 2013). Upon co-expression of CaM$_{1234}$, this baseline binding is weakened ~11 fold, yielding a relative affinity of $47153 \pm 4815$ $D_{\text{free}}$ units (Figure 3F). By contrast, co-expression of stac3 did not appreciably perturb CaM binding to the CI module with $K_{d,\text{EFF}} = 4182 \pm 330$ $D_{\text{free}}$ units (Figure 3G). These results suggest that both stac and CaM act concurrently via distinct sites on the channel carboxy-tail, in contradiction with a competitive mechanism.

**Elementary mechanisms underlying stac-regulation of CaV1**

Beyond Ca$^{2+}$-dependent regulation, apoCaM binding tunes the baseline activity of CaV channels (Adams et al., 2014). Absent stac, CaV1 lacking prebound CaM adopts a low $P_O$ configuration (empty configuration, $P_{O\text{(E)}}$) while apoCaM binding switches channels into a high $P_O$ mode (CaM-bound configuration, $P_{O\text{(D)}}$) (Adams et al., 2014). Ca$^{2+}$/CaM divests this initial enhancement in $P_O$.
and returns channels into a low $P_o$ gating mode ($P_{O/E}$) manifesting as CDI. The addition of stac as a regulatory agent enriches this modulatory scheme (Figure 4A). Three distinct scenarios may underlie suppression of $Ca^{2+}$-regulation by stac (Figure 4B): (1) stac binding may pre-inhibit channels into the low $P_o$ configuration ($P_{O/E}$) akin to $Ca^{2+}$-inactivated channels and prevent further $Ca^{2+}$-modulation, (2) stac may obstruct $Ca^{2+}$/CaM regulation while allowing apoCaM to change baseline $P_o$, (3) stac binding may allosterically lock channels into a high $P_o$ mode irrespective of CaM-binding status. For Scenario 3, it is possible that the baseline $P_o$ of Cav1.3 with stac may be distinct from that observed with CaM-overexpression. These three scenarios may be distinguished at the single-molecule level by assessing $CaV_{1.3}$ under various CaM-bound conditions using low-noise electrophysiology.

First, we analyzed $CaV_{1.3}$ in the presence and absence of stac (Figure 4C–E) to determine whether stac may promote channel entry into a low $P_o$ gating configuration. $CaV_{1.3}$ is typically pre-bound to CaM at endogenous CaM concentrations given its high affinity (Adams et al., 2014). $Ba^{2+}$...
Figure 4. Stac enhances the $P_O$ of Cav1.3. (A) A general four-state scheme for stac and CaM modulation. (1) Cav1.3 devoid of CaM and stac possess a low baseline $P_O$ ($P_{O/E}$). (2) Without stac, apoCaM binding to Cav1.3 upregulates baseline $P_O$ ($P_{O/A}$). Baseline $P_O$ of Cav1.3 bound to stac in the absence (configuration 3, $P_{O/E*}$) and the presence of apoCaM (configuration 4, $P_{O/A*}$) are unknown. (B) Schematic outlines three mechanistic
possibilities for stac binding to CaV1 and their functional outcomes. Scenario 1, stac uniformly suppresses $P_O$ of CaV1 ($P_O$<sub>1</sub>) and abolishes CDI. Scenario 2, apoCaM tunes baseline $P_O$ of CaV1 despite concurrent stac binding. Stac, nonetheless, abrogates CDI. Scenario 3, stac uniformly upregulates the baseline $P_O$ of CaV1 and abolishes CDI ($P_O$<sub>1</sub>)(C) Top, cartoon shows the canonical CaV1.3<sub>5</sub> variant with a high apoCaM binding affinity. Single-channel analysis of recombinant CaV1.3<sub>5</sub> in the absence (middle) and presence of stac (bottom). In both panels, the unitary Ba<sup>2+</sup> currents during voltage-ramp are shown between ~50 mV and +40 mV (planted gray lines, GHK fit). Robust CaV1.3 openings are detected in the absence and presence of stac. (D) Average single-channel $P_O$-voltage relationship for CaV1.3<sub>5</sub> obtained from multiple patches in the absence (gray) and presence of stac (blue). Error bars indicate ±S.E.M. for specified number of patches and 80–150 stochastic records per patch. (E) Histogram shows distribution of single-trial average $P_O$ ($P_O$) for the voltage range -30 mV ≤ $V$ ≤ +25 mV under control (top), stac-bound (middle), and CaM-bound (bottom) conditions. $P_O$-distribution is bimodal in the absence of stac corresponding to high $P_O$ (gray) and low $P_O$ (rose) gating modes. With stac, $P_O$-distribution is largely restricted to the high $P_O$ mode. (F–H) Single-channel analysis of a recombinant CaV1.3<sub>RNA-edited</sub> variant reveals a marked upregulation in the baseline $P_O$ in the presence of stac compared with control conditions in which apoCaM preassociation is weak. Absent stac or CaM, single-trial $P_O$-distribution is restricted to the low $P_O$ limits. With either stac or CaM, the high $P_O$ gating mode re-emerges. Format as in (C–E). (I–K) Stac also upregulates the baseline $P_O$ of CaV1.3<sub>L</sub>, an alternatively spliced variant, by stabilizing the high $P_O$ gating configuration. Format as in (C–E).

DOI: https://doi.org/10.7554/eLife.35222.008

The following figure supplements are available for figure 4:

**Figure supplement 1.** Extended data show that stac2 preferentially biases a high $P_O$ gating mode for CaV1.3.

DOI: https://doi.org/10.7554/eLife.35222.009

**Figure supplement 2.** Extended data show that stac2 and CaM enhance the $P_O$ of CaV1.3<sub>RNA-edited</sub> variant via discreet transitions into a high $P_O$ gating mode.

DOI: https://doi.org/10.7554/eLife.35222.010

**Figure supplement 3.** Extended data show that both stac2 and CaM enhance the $P_O$ of CaV1.3<sub>L</sub> variant.

DOI: https://doi.org/10.7554/eLife.35222.011

is used as a charge carrier to estimate baseline behavior of channels without confounding effects of CDI. A slow voltage-ramp (shown between ~50 and +40 mV) evokes stochastic channel openings that approximate near steady-state $P_O$ at each voltage. Stochastic records displayed in Figure 4C show channel openings as downward deflections to the open level (gray curves) and closures correspond to the zero-current portions of the trace. Robust openings are detected both in the presence and absence of stac (Figure 4C). To estimate the steady-state $P_O$ – voltage relationship, we averaged many stochastic records to obtain a mean current that is divided into the open level and averaged over multiple patches. CaV1.3<sub>5</sub> variant exhibits high $P_O$ in the absence of stac (Figure 4D) (Adams et al., 2014). Upon stac2 co-expression, the open probability remains high with ~10 mV hyperpolarizing shift in the voltage-dependence of activation (Figure 4D). We scrutinized single-channel trials to assess changes in gating modes. Figure 4—figure supplement 1 displays 10 sequential trials of CaV1.3 single-channel activity evoked by voltage-ramps introduced at 12 s intervals both in the presence and absence of stac. In the absence of stac, CaV1.3<sub>5</sub> activity switches between epochs of high and low activity, as evident from the diary plot of average $P_O$ within individual trials ($P_O$) (Figure 4—figure supplement 1B). Analysis of single-trial $P_O$ distribution reveals a bimodal distribution denoting discrete high and low $P_O$ gating modes (Figure 4E). Upon stac overexpression, channel activity is high as evident from $P_O$-diary plots (Figure 4—figure supplement 1D) and single-trial $P_O$ distribution (Figure 4E). In contradiction with Scenario 1, stac-bound channels are not pre-inhibited; rather, channels preferentially adopt a high $P_O$ mode.

To distinguish between the second and third mechanistic possibilities, we considered CaV1.3 variants with weakened apoCaM binding affinity that largely reside in the low $P_O$ configuration (Adams et al., 2014). Accordingly, we tested the baseline $P_O$ of CaV1.3<sub>MODY</sub>, an RNA-edited variant whose central isoleucine within the IQ domain is substituted to a methionine, (Bazzazi et al., 2013; Huang et al., 2012) and an alternative splice variant CaV1.3<sub>L</sub> containing an autoinhibitory domain that competitively displaces CaM (Liu et al., 2010; Singh et al., 2008). In the absence of stac and under endogenous CaM levels, both CaV1.3<sub>MODY</sub> (Figure 4F–G) and CaV1.3<sub>L</sub> (Figure 4I–J) open sparsely, exhibiting a diminished maximal $P_O$ consistent with channels lacking CaM (Adams et al., 2014; Bock et al., 2011). Indeed, single-channel trials of CaV1.3<sub>MODY</sub> (Figure 4—figure supplement 2A–C) and CaV1.3<sub>L</sub> (Figure 4—figure supplement 3A–C) under endogenous levels of CaM reveal uniformly low activity, with single-trial $P_O$ distribution restricted to low limits (Figure 4H for CaV1.3<sub>MODY</sub>; Figure 4K for CaV1.3<sub>L</sub>). CaM overexpression with both channel variants reveals the resurgence
of epochs of high activity (Figure 4—figure supplement 2D–E; Figure 4—figure supplement 3D–E) and a bimodal P_o distribution with a substantial fraction of trials corresponding to a high P_o configuration (Figure 4H and K for Ca_v1.3MODY and Ca_v1.3L, respectively). Upon stac co-expression, robust channel openings re-emerge for both Ca_v1.3MODY (Figure 4F–G) and Ca_v1.3L (Figure 4I–J) yielding an enhanced baseline P_o akin to Ca_v1.3L variant (Adams et al., 2014). Scrutiny of single-channel trials for both channel variants reveal uniformly high channel activity (Figure 4—figure supplement 2F–G for Ca_v1.3MODY; Figure 4—figure supplement 3F–G for Ca_v1.3L) and single-trial P_o distributions are now within the high activity limits (Figure 4H and K) reminiscent of the CaM overexpression. The steady-state P_o-V relations for Ca_v1.3L, Ca_v1.3MODY, and Ca_v1.3L in the presence of stac closely approximate each other (Figures 4D, G and J). These findings demonstrate that consistent with Scenario 3, stac-binding locks Ca_v1.3 channels in the high P_o configuration and effectively decouples the channel pore from CaM-dependent conformational changes. Moreover, these results highlight the dominance of stac over CaM in Ca_v1 modulation.

U-domain constitutes a minimal motif for Ca_v1 CDI suppression

With elementary mechanisms discerned, we turned to identify stac motifs functionally critical for allosteric suppression of CaM-regulation. Structurally, stac isoforms share a modular architecture composed of a C1 domain linked to two SH3 domains via a largely unstructured linker segment (U-linker region) (Suzuki et al., 1996). As these modular subcomponents typically recognize distinct ligands, we reasoned that their molecular functions may be separable (Cohen et al., 1995; Colon-Gonzalez and Kazanietz, 2006). We trisected stac2 to assess whether individual subcomponents can recapitulate functional regulation. We focused initially on C1 and tandem SH3 domains as these segments were recently shown to be critical for Ca_v1.1 binding and triadic localization in skeletal muscle (Campiglio and Flucher, 2017; Wong King Yuen et al., 2017). Co-expression of either segment, however, only minimally perturbed CDI of Ca_v1.2-CaM (Figures 5A, C and D; Figure 5—figure supplement 1A–1C). By contrast, the linker region by itself fully abolished CDI of these channels (p=8.9 × 10^-6, Figure 5B and D; Figure 5—figure supplement 1D), recapitulating the effect of stac2 on Ca_v1.2.

To localize functional segments within the U-linker, we undertook bioinformatic analysis to identify highly conserved regions. We performed multiple sequence alignment of complete sequences of 770 stac orthologs using the MUSCLE algorithm (Edgar, 2004) and subsequently computed an empirical measure for the degree of protein sequence conservation at each position. The degree of conservation is defined as the likelihood of observing the consensus residue at each sequence position divided by the number of distinct residues observed at this position. By this algorithm, perfectly conserved residues will yield a unitary value, whereas poorly conserved residues will have a lower score. We identified a 22-amino acid stretch, termed the U-domain (‘unknown’ domain), exhibiting high conservation (Figure 5E, blue shaded region). Co-expression of U-domain diminishes CDI of both Ca_v1.2-CaM and Ca_v1.3-CaM (Figure 5F–H, Figure 5—figure supplement 1E–G). Thus informed, we undertook systematic alanine scanning mutagenesis of the stac2 U-domain to identify key residues (Figure 5I; Figure 5—figure supplement 2). Co-expression of mutant stac2 with triple alanine substitution of residues ET[206-208] resulted in minimal disruption of Ca_v1.2 and Ca_v1.3 CDI (Figure 5J–K), suggesting that these residues are necessary. Further analysis revealed residues P[VY[203-205] and KVD[200-202] to be critical for stac function (Figure 5I; Figure 5—figure supplement 2A–2C). Residues outside these loci minimally affected stac modulation of Ca_v1 (Figure 5I; Figure 5—figure supplement 2D–G). These findings confirm the necessity and sufficiency of U-domain as a minimal motif for preventing CaM-regulation of Ca_v1.

U-domain modulates native Ca_v1 and reshapes cardiac action potentials

Having identified a minimal U-domain for CDI suppression, we sought to assess potential physiological consequences of stac regulation in cardiac myocytes. As stac expression is yet to be identified in myocytes, we first probed its presence using immunohistochemistry with stac1- and stac2-specific antibodies. To ensure that the two antibodies reliably probe the two isoforms, we first evaluated the ability to detect stac isoforms exogenously expressed in HEK293 cells (Figure 6—figure supplement 1). Untransfected cells show minimal stac1 and stac2 immunostaining (Figure 6—figure supplement 1A–B), as confirmed by confocal imaging and population data. By contrast, immunostaining with
stac1 antibody shows labeling with cells expressing stac1 but not stac2 or stac3. Similarly, labeling with stac2 antibody reveals substantial fluorescence (F > 300) in cells transfected with stac2 but not stac1 or stac3. Thus informed, we assessed expression and localization of stac isoforms in cardiac myocytes (Figure 6—figure supplement 1C–F). Analysis of acutely dissociated adult guinea pig ventricular myocytes (aGPVMs) showed stac2 labeling but not stac1 (Figure 6—figure supplement 1C). Consistent with these findings, immunoblotting with stac2 antibody showed ~50 kDa signal in stac2-transfected HEK293 cells but absent from untransfected cells, confirming the ability of the antibody to detect stac2 (Figure 6—figure supplement 1G). Analysis of aGPVM lysate revealed likely...
endogenous stac2 with a similar molecular weight to that of recombinant stac2 in HEK293 cells (Figure 6—figure supplement 1G).

Given this baseline expression, we next considered potential effects of fluctuations in ambient stac levels. We synthesized the U-domain of stac2 as a peptide and delivered it via pipette dialysis to acutely elevate the myocyte’s cytosolic concentration. We validated the synthesized peptide by testing its effect on recombinant CaV1.2 expressed in HEK293 cells (Figure 6A). Following pipette dialysis of the U-peptide, CDI of CaV1.2 was reduced as evident from exemplar currents and population data (Figure 6B–C; Figure 6—figure supplement 2A–B). Thus affirmed, we isolated ventricular myocytes from adult guinea pigs as evident from exemplar traces and bar graph summary of population data. To eliminate T-type current, the cells were depolarized to $-40\text{ mV}$ for a period of 100 ms. Format as in (A–C).

Figure 6. Synthetic U-domain peptide is sufficient for physiological perturbations. (A) Schematic illustrates pipette dialysis of custom synthesized U-domain peptide in CaV1.2 heterologously expressed in HEK293 cells, a strategy that emulates acute elevation of cytosolic stac2 levels. (B–C) Exemplar traces and population data confirm that pipette dialysis of U-domain suppresses CDI of recombinant CaV1.2 in HEK293 cells. Format as in Figure 1A–B. Control relation in (C) is duplicated from Figure 1B. (D–F) Pipette dialysis of U-motif as a peptide abolishes CDI of endogenous L-type current in freshly dissociated ventricular myocytes from adult guinea pigs as evident from exemplar traces and bar graph summary of population data. To eliminate T-type current, the cells were depolarized to $-40\text{ mV}$ for a period of 100 ms. Format as in (A–C). (G) Exemplar action potential traces of aGPVMs paced at 0.5 Hz with (blue) and without (black) 0.5 mM U-domain in the internal solution. In the presence of U-domain, the action potentials are markedly prolonged (blue shaded area) consistent with a loss of CDI of native L-type current. (H) Complement of cumulative distribution (P(APD_{80}>t)) of action potential durations (APD_{80}) obtained in the presence (blue) and absence (black) of U-domain in the internal solution.

DOI: https://doi.org/10.7554/eLife.35222.015

The following figure supplements are available for figure 6:

Figure supplement 1. Baseline expression of stac in cardiac myocytes.
DOI: https://doi.org/10.7554/eLife.35222.016

Figure supplement 2. Pipette dialysis of U-motif as a peptide abolishes CDI of both recombinant and native L-type currents in ventricular myocytes.
DOI: https://doi.org/10.7554/eLife.35222.017
myocytes from adult guinea pigs (aGPVMs) to probe changes in CDI of native CaV channels and action potential duration in response to changes in stac levels (Figure 6D). Devoid of U-domain peptide, endogenous Ca\(^{2+}\) currents in ventricular myocytes displayed CDI, establishing baseline levels of CaM-regulation (Figure 6E, Figure 6—figure supplement 2D). Pipette dialysis of U-peptide reduced CDI in myocytes (Figure 6E-F, Figure 6—figure supplement 2E). The reduction in overall inactivation of Ca\(^{2+}\) currents suggest that fluctuations in stac levels may markedly alter action potential waveforms. To test this possibility, we obtained current-clamp recordings of aGPVMs and compared action potential waveforms in the presence and absence of U-peptide. Figure 6G shows typical voltage profiles of action potentials in aGPVMs paced at 0.5 Hz. Waveforms are stable between traces and the mean action potential duration (APD\(_{80}\)), the duration of time when the action potential is at least 80% of its peak voltage, is 277.9 ± 31.37 ms (mean ±S.E.M., n = 6). Figure 6H displays the complement of the cumulative distribution of APD\(_{80}\). When the peptide is added to the internal solution, APD\(_{80}\) is enhanced to 740.1 ± 105.49 ms (n = 6) (Figure 6G–H). Thus, the U-peptide both alters the CDI of endogenous cardiac CaV1, prolongs APD, and may ultimately destabilize rhythmicity of the heart.

**Fhf selectively abrogate CaM signaling to NaV1**

Encouraged by the selectivity of stac for CaV1, we sought to identify other regulatory proteins that may tune CaM-signaling to related channel families. However, recognizing such modulators amidst ion channel signalosomes is challenging. Given that stac interacts with CaV1 CI module via the PCI element, we reasoned that other CaV and NaV interacting proteins that engage a similar interface may suppress CaM-feedback. Intriguingly, recent atomic structures show that fhf interacts with NaV1 CI module via the PCI interface (Figure 7A) (Wang et al., 2012). Yet, functionally, fhf isoforms are thought to modulate only voltage-dependent gating properties, with effects on Ca\(^{2+}\)/CaM-regulation unknown (Goldfarb et al., 2007; Lou et al., 2005; Wang et al., 2012). To test whether fhf alters NaV CDI, we undertook quantitative Ca\(^{2+}\) photo-uncaging of the skeletal muscle NaV1.4 isoform. We focused here on fhf1b given its modest baseline expression in skeletal muscle and pathological enrichment in critical illness myopathies (Kraner et al., 2012). Figure 7B reproduces baseline levels of CDI for NaV1.4 under control conditions. Co-expression of fhf1b abolished CDI (Figure 7B–C; Figure 7—figure supplement 1A), unveiling a novel role of fhf in tuning Ca\(^{2+}\)-feedback of NaV channels. To assess selectivity, we probed whether fhf alters CDI of CaV1.3. In comparison to control conditions, fhf co-expression spared CaV1.3 CDI (Figure 7D–E; Figure 7—figure supplement 1B) suggesting that fhf may be a selective modulator of NaV1.

Mechanistically, functional results along with atomic structures of NaV1 CI bound to CaM and fhf yield insights on mechanisms for CDI suppression (Gabelli et al., 2014; Wang et al., 2012; Wang et al., 2014). Both fhf and CaM bind concurrently to NaV1 CI (Wang et al., 2012; Wang et al., 2014), with fhf binding triggering a conformational rearrangement of CaM (Figure 7A) (Gabelli et al., 2014; Wang et al., 2012). To experimentally validate allostery, we followed our strategy with CaV1.3 and tethered CaM to NaV1.4 carboxy-tail. Reassuringly NaV1.4-CaM exhibits robust baseline CDI (Figure 7F; Figure 7—figure supplement 1C). Whereas dominant negative CaM\(_{1234}\) typically abolishes CDI of NaV1.4 (Ben-Johny et al., 2014), NaV1.4-CaM exhibits robust CDI despite CaM\(_{1234}\), confirming the protective nature of tethered CaM against competitive inhibitors (Figure 7G; Figure 7—figure supplement 1D). Co-expression of fhf1b, however, reduces CDI of NaV1.4-CaM (Figure 7F–G; Figure 7—figure supplement 1E). Thus, like stac modulation of CaV1, fhf overrides CaM signaling to NaV1.4 despite a tethered CaM, suggesting that fhf acts in allostery.

To garner a structural perspective, we turn to NaV1.5 CI/fhf complex (Figure 7A) as the atomistic basis of the stac/CaV1 CI interaction is unknown (Wang et al., 2012; Wang et al., 2014; Wong King Yuen et al., 2017). Whereas the dual-vestigial EF hand segments of NaV1.5 and CaV1.1 are similar (Figure 7H–I), the fhf binding interface of NaV1.5, including the preQ loop diverges from corresponding segments of CaV1.1 and introduces a steric clash (Figure 7I–J) (Wang et al., 2012; Wu et al., 2016). Thus, by leveraging structurally distinct loci on the CI module, fhf selectively diminish CaM signaling to NaV channels. These findings point to a class of auxiliary proteins that selectively adjust Ca\(^{2+}\)-dependent feedback to individual ion channel targets.
Figure 7. Fhf uses an allosteric mechanism to abrogate Ca\(^{2+}\)-feedback of Na\(_{v}1.4\). (A) Structural comparison of Na\(_{v}1.5\) CI (green) in the presence of CaM alone (cyan, left) or both CaM (cyan) and fhf1b (purple). Fhf binding changes baseline conformation of CaM on Na\(_{v}1.5\) CI. (B–C) Co-expression of fhf1b abolishes CDI in Na\(_{v}1.4\) evoked via Ca\(^{2+}\) photo-uncaging. Format as in Figure 1M–N. Control data are reproduced from Figure 1M–N for comparison. (D–E) In sharp contrast, strong overexpression of fhf1b does not alter CDI of Ca\(_{v}1.3\)\(_{S}\). Format as in Figure 1A–B. Control data reproduced from Figure 1D for comparison. (F–G) Fhf1 suppresses CDI of Na\(_{v}1.4\) tethered to CaM. Fusion of CaM protects Na\(_{v}1.4\) from competitive inhibitors such as CaM\(_{1234}\) (G). Format as in Figure 1M–N. (H) Structure of Ca\(_{v}1.1\) upstream CI elements (blue) composed of dual vestigial EF hands and preIQ segments isolated from cryo-EM structure of Ca\(_{v}1.1\) (PDBID, 5GJV). This domain is the primary interface for stac interaction in the Ca\(_{v}1.1\) CI. (I) Structural overlay of upstream CI elements of Ca\(_{v}1.1\) (PDBID, 5GJV) and Na\(_{v}1.5\) (PDBID, 4DCK) shows highly conserved dual vestigial EF hand segments while the fhf binding site is structurally...
Engineering synthetic modulation of \( \text{Ca}_V \) channels

As both stac and fhf tune \( \text{Ca}^{2+} \)-feedback to individual \( \text{Ca}_V \) and \( \text{Na}_V \) targets by interacting with respective PCI segments, this mechanism furnishes a strategy to engineer synthetic channel modulators. We reasoned that introducing a short interaction motif into the PCI locus may permit inhibition of \( \text{Ca}_V \) \( \text{Ca}^{2+} \)-feedback by a novel protein. We chose the well-characterized RxxK motif from SLP-76 for its small size and high-affinity interaction with SH3 domain of Mona \( \text{Harkiolaki et al., 2003} \) \( \text{Figure 8A} \). Co-expression of Mona SH3 with wildtype \( \text{Ca}_V1.3_S \) demonstrated the persistence of CDI, confirming the suitability of these channels as a ‘blank slate’ to confer synthetic modulation \( \text{Figure 8B–C; Figure 8—figure supplement 1A} \). We replaced a 12-residue segment in the preIQ domain with the RxxK motif, as highlighted in \( \text{Figure 8A} \), yielding \( \text{Ca}_V1.3_{\text{RxxK}} \) engineered channels. As this locus is situated upstream of the IQ domain, this maneuver spares apoCaM prebinding. Under endogenous levels of CaM, \( \text{Ca}_V1.3_{\text{RxxK}} \) exhibit robust baseline CDI \( \text{Figure 8D–E; Figure 8—figure supplement 1B} \). Co-expression of Mona SH3 with \( \text{Ca}_V1.3_{\text{RxxK}} \) markedly diminished CDI \( \text{Figure 8D–E; Figure 8—figure supplement 1B} \), thus revealing engineered CDI suppression. These findings illustrate the versatility of the CI module as a regulatory hub and highlight the feasibility of developing synthetic modulators to tune \( \text{Ca}^{2+} \)-feedback of ion channels.

Discussion

CaM is a dynamic regulator of \( \text{Ca}_V1 \), \( \text{Ca}_V2 \), and \( \text{Na}_V1 \), affording millisecond-precision \( \text{Ca}^{2+} \)-feedback of channel activity. Our findings suggest that distinct auxiliary regulatory proteins tune CaM signaling to individual targets selectively. Stac prevents CaM signaling to \( \text{Ca}_V1 \), while fhf reduces signaling to \( \text{Na}_V1 \) \( \text{Figure 8F} \). Parallel analysis of the two proteins delineates mechanisms and sets the stage for in-depth physiological analysis.

Relationship to prior studies of stac-\( \text{Ca}_V \) modulation

Stac regulation of \( \text{Ca}_V1 \) modifies multiple aspects of \( \text{Ca}_V1 \) function. For \( \text{Ca}_V1.1 \), stac3 enhances plasmalemmal trafficking \( \text{Linsley et al., 2017b; Niu et al., 2018; Polster et al., 2015; Wong King Yuen et al., 2017; Wu et al., 2018} \), and promotes conformational coupling to RyR \( \text{Linsley et al., 2017a; Polster et al., 2016} \). For \( \text{Ca}_V1.2 \), however, stac1-3 isoforms slow inactivation \( \text{Campiglio et al., 2018; Polster et al., 2015; Wong King Yuen et al., 2017} \). Our work generalizes the latter effect to the \( \text{Ca}_V1 \) family and further identifies a change in baseline channel openings \( \text{P}_0 \).

A few mechanistic nuances merit attention. First, stac binds to multiple \( \text{Ca}_V1 \) segments including (1) the II-III linker \( \text{Polster et al., 2018; Wong King Yuen et al., 2017} \), (2) the III-IV linker \( \text{Figure 2D} \), and (3) the carboxy-tail \( \text{Figure 2D} \) \( \text{Campiglio et al., 2018; Niu et al., 2018} \). Previous studies have shown that stac interaction with the II-III linker is important for \( \text{Ca}_V1 \) trafficking in skeletal muscle \( \text{Polster et al., 2018; Wong King Yuen et al., 2017} \). Chimeric analysis here suggests that stac interaction with the carboxy-tail is critical for tuning CDI. Prior analysis of \( \text{Ca}_V1.2 \) triadic localization in myotubes suggested that the channel IQ domain may be important for stac binding \( \text{Campiglio et al., 2018} \). However, FRET 2-hybrid assay indicates that stac interaction with the IQ is around tenfold weaker than with the PCI segment. Second, prior work also suggested that stac-mediated reduction in CDI results from competitive displacement of CaM by stac \( \text{Campiglio et al., 2018} \). Functional experiments using \( \text{Ca}_V1 \) tethered to CaM, however, suggest that stac does not compete with CaM. Consistent with this scheme, FRET 2-hybrid analysis shows that CaM binding with the CI module is intact even in the presence of stac. Third, key domains within stac relevant for \( \text{Ca}_V \) modulation remain controversial. Previous studies have identified the dual SH3 and C1 domains.
to be critical for stac effect on trafficking and coupling to RyR (Campiglio and Flucher, 2017; Linsley et al., 2017a; Linsley et al., 2017b; Polster et al., 2016), while the C1 has been proposed to be critical for modifying CaV1 CDI (Campiglio et al., 2018; Wong King Yuen et al., 2017). Our findings instead suggest that the U-domain in the stac2 linker region is sufficient to fully recapitulate reduction in CaV1 CDI. Notably, prior analysis of the C1 domain also included this linker (Wong King Yuen et al., 2017). Given these experimental findings, a simple possibility is that distinct subdomains within stac interact with disparate channel segments to support multifunctionality of stac. While the U-domain modifies channel inactivation, other subdomains may support plasmalemmal trafficking and conformational coupling.

Figure 8. Engineering synthetic modulation of CaV1 channels. (A) Left, schematic shows the atomic structure of Mona SH3 domain in complex with RxxK motif. Right, sequence alignment outlines strategy for insertion of RxxK motif into CaV1, yielding CaV1.3RxxK to confer synthetic suppression of CaV1.3 CDI by Mona SH3. (B–C) CaV1.3S expressed with and without Mona SH3 shows full CDI, confirming that wildtype CaV1.3 CDI is insensitive to Mona SH3. Format as in Figure 1A–B. Control data are reproduced from Figure 1D for comparison. (D–E) Mona SH3 strongly diminishes CDI of CaV1.3RxxK. Format as in Figure 1A–B. (F) Cartoon summarizes selective modulation of Ca2+/CaM signaling to CaV1, and NaV1 channels with CaM, stac, and fhf.

DOI: https://doi.org/10.7554/eLife.35222.020

The following figure supplement is available for figure 8:

Figure supplement 1. Extended data demonstrate feasibility of engineering synthetic modulators of CaM signaling to CaV1.3.

DOI: https://doi.org/10.7554/eLife.35222.021
Defining a general class of auxiliary modulators of CaM signaling

Although functionally divergent, CaV1, CaV2, and NaV1 feature a modular CI element with a common CaM interaction fingerprint and subsequently, shared mechanistic basis for Ca\(^{2+}\)-regulation. For all three families, apoCaM prebinds the CI module while Ca\(^{2+}\)/CaM interaction switches channels between discrete high and low \(P_\text{o}\) gating modes (Ben-Johny et al., 2015). How do allosteric regulators override CaM-signaling? First, stac and fhf use unique interfaces on the channel CI to selectively tune Ca\(^{2+}\)-feedback. Second, stac locks CaV1 into a high \(P_\text{o}\) gating mode irrespective of whether apoCaM or Ca\(^{2+}\)/CaM is bound, effectively disengaging the pore from CaM-conformational changes. For NaV1, despite fhf binding, CaM undergoes a profound Ca\(^{2+}\)-dependent rearrangement (Wang et al., 2012; Wang et al., 2014) suggesting that fhf does not prevent Ca\(^{2+}\) binding to CaM or Ca\(^{2+}\)/CaM interaction with effector interfaces. Instead, like stac and CaV1, fhf may override CaM-dependent changes to Nav, akin to a clutch disengaging power transmission in mechanical systems. As fhf elicits a change in apoCaM conformation (Figure 7A) (Gabelli et al., 2014; Wang et al., 2012), baseline gating of NaV may also be altered (Goldfarb et al., 2007; Lou et al., 2005). This parallelism between stac and fhf hints at a shared mechanism.

Ca\(^{2+}\)-binding proteins (CaBPs) (Haeseleer et al., 2000) also suppress CaM signaling to CaV1 (Lee et al., 2002; Yang et al., 2006). Mechanistically, CaBPs exploit a mixed allosteric scheme – at low concentrations, they engage distinct interfaces from CaM but at higher concentrations displace CaM (Findeisen and Minor, 2010; Oz et al., 2013; Yang et al., 2014). The existence of other regulatory proteins that curtail Ca\(^{2+}\)-feedback points to a general class of auxiliary regulators of CaM-signaling to targets beyond NaV and CaV1. Identifying such molecular players is critical to understand how CaM signaling is orchestrated.

Biological implications of stac modulation of CaV1

Stac1/2 isoforms are widely expressed in multiple brain regions, including both the hippocampus and the midbrain (Nelson et al., 2013; Suzuki et al., 1996). Our experiments hint at low basal stac2 expression in guinea pig ventricular cardiac myocytes, although previous studies have failed to detect stac2 in murine heart (Nelson et al., 2013). Further quantitative analysis will help establish ambient stac levels including species-specific differences and potential modulatory effects on cardiac function. Interestingly, endogenous CaV1 in both hippocampal and midbrain neurons (Bazzazzi et al., 2013; Oliveria et al., 2012) as well as ventricular cardiac myocytes exhibit CDI. As all stac variants shunted CDI of CaV1 in HEK293, it is possible that stac function may be tightly regulated in native settings. One possibility is that stac abundance may be tuned developmentally (Suzuki et al., 1996), pathologically, or via interacting proteins (Satoh et al., 2006). For instance, the transcription factor, NFAT binds to an upstream promoter region of stac2 gene to upregulate stac2 expression in osteoclasts as well as during hypoxic conditions in neural stem cells (Jeong et al., 2018). Experimentally, this importance is inferred from prolongation of action potentials upon expression of mutant CaM1234 (Alseikhan et al., 2002). Yet, constitutive CaM expression may yield nonspecific effects (Hall et al., 2013; Wang et al., 2007) that obscure the net contribution of CaV1 CDI (Zhang et al., 2015). Acute elevation of the U-domain bypasses these ambiguities and confirms a key role for CaV1 CDI for cardiac action potentials. Pathophysiologically, differential expression of stac2 has been reported in right ventricular heart failure, hinting at a potential role in calcium remodeling during heart failure (di Salvo et al., 2015).

Post-transcriptional modification of CaV1.3 generates an assortment of variants with modified carboxy-termini (Bock et al., 2011; Huang et al., 2012). The apoCaM affinities of these variants are such that CaM fluctuations may redistribute channels between populations lacking or endowed with
apoCaM (Bazzazi et al., 2013), evoking concomitant changes in maximal $P_O$ and CDI of CaV1.3 (Adams et al., 2014). Stac uniformly locks these variants into a high $P_O$ configuration incapable of CDI, thereby supporting reliable and persistent Ca$^{2+}$-influx in spite of CaM. Notably, functional effects of CaV1.3 alternative splicing have been shown to be cell-type specific suggesting that auxiliary regulators may tune channel properties (Scharinger et al., 2015). Fitting with these regulatory possibilities, disruption of stac modulation of CaV1.3 in Drosophila alters circadian rhythm (Hsu et al., 2018).

**Biological implications of fhf modulation of NaV1**

Unlike canonical fibroblast growth factors, fhf lack a secretory signal sequence (Smallwood et al., 1996) and serve as intracellular proteins (Schoorlemmer and Goldfarb, 2001). Four distinct fhf isoforms have been identified with tissue-specific expression in neurons, cardiomyocytes, and skeletal muscle (Goldfarb, 2005; Kraner et al., 2012; Smallwood et al., 1996). Functionally, fhf isoforms promote NaV1 trafficking and fast inactivation (Pablo and Pitt, 2016). More specifically, fhf adjust steady-state voltage-dependence of inactivation (Lou et al., 2005), elicit a kinetically distinct long-term inactivation (Dover et al., 2010), and modify resurgent current (Yan et al., 2014). Our present findings suggest that fhf1 also tunes CDI of NaV1. Physiologically, NaV CDI may be prominent during repetitive activity, as excess Ca$^{2+}$ accumulation may inhibit Na currents. Thus, suppression of NaV1 CDI by fhf may enhance repetitive firing. Interestingly, loss of fhf1 and/or fhf4 result in diminished firing properties of cerebellar Purkinje neurons (Bosch et al., 2015; Goldfarb et al., 2007), while loss of fhf2 reduces cardiac conduction (Park et al., 2016; Wang et al., 2011a). It is possible that loss of fhf may enhance net CDI thus contributing to diminished excitability in these cells. As mutations in fhf1 are associated with epileptic encephalopathy (For CENetDDD Study group‡* et al., 2016) and cardiac conduction disorders (Hennessey et al., 2013) while mutations in fhf4 are linked to spinocerebellar ataxia (Brusse et al., 2006), resolving the dynamic interplay between CaM and fhf in tuning NaV1 may be critical for understanding pathogenic mechanisms.

**New strategy for synthetic ion channel modulation**

Finally, our results highlight the possibility of engineering synthetic regulation to tune CaM signaling.

While CaV1.3 is insensitive to Mona SH3, insertion of an RxxK motif (Harkiolaki et al., 2003) into the carboxy-tail preIQ segment allows latent modulation by Mona SH3. Given the structural similarity of the CI modules of CaV1, CaV2, and NaV1, and sequence variability within the preIQ domain, emerging protein engineering methods may be used to screen for synthetic modulators of related ion channel families. As the ligand specificity of SH3 domains can be custom-engineered (Nguyen et al., 2000) and subcellular localization tuned via targeting motifs (Komatsu et al., 2010), a custom library of synthetic regulators may be developed to combinatorially modify kinetic properties of CaV1, CaV2, or NaV1 channels with spatiotemporal specificity. Generalizing this approach may lead to the development of new tools to manipulate Ca$^{2+}$ signaling.

In all, our findings unravel the elegant interplay between a novel class of allosteric regulators and CaM in orchestrating the activity of CaV and NaV channels.

---

### Materials and methods

**Key resources table**

| Reagent type (species or resource) | Designation | Source or reference | Identifiers | Additional information |
|-----------------------------------|-------------|---------------------|-------------|------------------------|
| Gene (rat) β2A                      | PMID: 1370480 | GenBank: M80545     |             |                        |
| Gene (rat) α2δ                      | PMID: 8107966 | NCBI: NM_012919     |             |                        |
| Gene (Oryctolagus cuniculus) CaV1.2 | PMID: 1718988 | NCBI: NM_001136522 |             |                        |
| Gene (rat) CaV1.3S                  | PMID: 20139964 | GenBank: AF370009.1 |             |                        |
| Gene (rat) CaV1.3MQDY               | PMID: 24120865, 22284185 |             |             |                        |

Continued on next page
| Reagent type (species) or resource | Designation | Source or reference | Identifiers | Additional information |
|-----------------------------------|-------------|--------------------|-------------|------------------------|
| Gene (human)                      | $\text{Ca}_v1.4_{43^*}$ | PMID: 22069316    |             | Laboratory of Dr. Soong Tuck Wah (National University of Singapore) |
| Gene (human)                      | $\text{Ca}_v2.1$ splice variant 37a(EFa) with 43'/44'/47' | PMID: 12451115 |             |                        |
| Gene (human)                      | $\text{Ca}_v2.2$ | PMID: 1321501, 10233069 | GenBank: M94172.1 |                        |
| Gene (rat)                        | $\text{Ca}_v2.3$ | PMID: 8388125, 18400181 | NCBI: NM_019294.2 |                        |
| Gene (rat)                        | $\text{Na}_v1.4$ | PMID: 2175278 |             |                        |
| Gene (human)                      | stac1        | Origene            | NCBI: NP_003140.1 |                        |
| Gene (mouse)                      | stac2        | Origene            | NCBI: NP_666140.1 |                        |
| Gene (human)                      | stac3        | Origene            | NCBI: NP_659501.1 |                        |
| Gene (human)                      | fnf          | PMID: 8790420     |             |                        |
| Gene (human)                      | Mona SH3     | PMID: 12773374    |             | Synthesized by Genscript based on sequence in publication |
| Peptide (mouse)                   | U-peptide    | this paper        |             | Peptide sequence KVDPVYETLRYGTSLALM NRSS synthesized by Genscript |
| Competent cells (E. coli)         | DH5α         | Invitrogen: 18265017 |             |                        |
| Cell line (human)                 | HEK293       | other             | RRID: CVCL_0045 | Generated from Hartley strain guinea pigs |
| Biological sample (guinea pig)    | aGPVM        | PMID: 24076394    |             |                        |
| Antibody                          | anti-stac1   | Abcam: ab181157   |             | 1:100                  |
| Antibody                          | anti-stac2   | Abcam: ab156080   |             | IHC – 1:100            |
| Antibody                          | anti-α-actinin | Sigma Aldrich: A7811 |             | WB – 1:250             |
| Antibody                          | goat anti-rabbit IgG Alexa Fluor 594 | Abcam: ab150080 | RRID: AB_476766 | 1:300                  |
| Antibody                          | goat anti-mouse IgG1 Alexa Fluor 488 | Thermo Fischer: A21121 | RRID: AB_2535764 | 1:1000                 |
| Antibody                          | Goat Anti-Rabbit IgG (H + L) | Jackson ImmunoResearch: 111-035-144 | RRID: AB_2307391 | 1:10,000               |
| Recombinant DNA reagent           | $\text{Ca}_v1.3_{L}$ | PMID: 20139964    |             | Engineered from $\text{Ca}_v1.3_{S}$ and human long distal carboxyl tail (NCBI: NM_000718) |
| Recombinant DNA reagent           | $\text{Ca}_v2.3/1.3$ CI | PMID: 24441587    |             |                        |
| Recombinant DNA reagent           | $\text{Ca}_v1.3$-$\text{CaM}_W$T | PMID: 24441587    |             |                        |
| Recombinant DNA reagent           | $\text{Ca}_v1.2$-$\text{CaM}_W$T | PMID: 15087548    |             |                        |

Continued on next page
| Reagent type (species) or resource | Designation | Source or reference | Identifiers | Additional information |
|-----------------------------------|-------------|--------------------|------------|-----------------------|
| Recombinant DNA reagent           | Na\textsubscript{v}1.4-CaM | this paper         |            | Engineered by fusing \textit{CaM}\textsubscript{WT} carboxy-tail of Na\textsubscript{v}1.4 |
| Recombinant DNA reagent           | Ca\textsubscript{v}1.3\textit{RxxK} | this paper         |            | Engineered from Ca\textsubscript{v}1.3 |
| Recombinant DNA reagent           | CFP-stac3 | this paper         |            | stac3 was cloned into CFP vector with NotI and XbaI |
| Recombinant DNA reagent           | YFP-Ca\textsubscript{v}1.3 CI | PMID: 23591884    |            |                                      |
| Recombinant DNA reagent           | YFP-Ca\textsubscript{v}1.3 PCI | PMID: 23591884    |            |                                      |
| Recombinant DNA reagent           | YFP-Ca\textsubscript{v}1.3 IQ | PMID: 23591884    |            |                                      |
| Recombinant DNA reagent           | Ven-C1 | this paper         |            | stac2 C1 was cloned into Venus vector (PMID: 26997269) with NotI and XbaI |
| Recombinant DNA reagent           | Ven-linker region | this paper         |            | stac2 linker region was cloned into Venus vector (PMID: 26997269) with NotI and XbaI |
| Recombinant DNA reagent           | Ven-SH3-SH3 | this paper       |            | stac2 SH3-SH3 was cloned into Venus vector (PMID: 26997269) with NotI and XbaI |
| Recombinant DNA reagent           | Ven-U-motif | this paper       |            | stac2 U-motif was cloned into Venus vector (PMID: 26997269) with NotI and XbaI |
| Recombinant DNA reagent           | stac2 (KVD/AAA) | this paper     |            | Quickchange PCR with stac2 |
| Recombinant DNA reagent           | stac2 (PVY/AAA) | this paper     |            | Quickchange PCR with stac2 |
| Recombinant DNA reagent           | stac2 (ETL/AAA) | this paper     |            | Quickchange PCR with stac2 |
| Recombinant DNA reagent           | stac2 (RYG/AAA) | this paper     |            | Quickchange PCR with stac2 |
| Recombinant DNA reagent           | stac2 (TSL/AAA) | this paper     |            | Quickchange PCR with stac2 |
| Recombinant DNA reagent           | stac2 (NRS/AAA) | this paper     |            | Quickchange PCR with stac2 |
| Recombinant DNA reagent           | stac2 (S/A) | this paper       |            | Quickchange PCR with stac2 |
| Sequence-based reagent            | Ven-C1 forward primer | this paper |            | cttctcgcgcgcgc tgtagccaaatga gcggaga |
| Sequence-based reagent            | Ven-C1 reverse primer | this paper |            | tcagaattctctattg tgtg gggagatctc |
| Sequence-based reagent            | Ven-linker region forward primer | this paper |            | cttctcgcgcgcgt ctctctctctctctctctct |
| Sequence-based reagent            | Ven-linker region reverse primer | this paper |            | tcagaattcttga gtatcg ggcggccaga |
| Sequence-based reagent            | Ven-SH3-SH3 forward primer | this paper |            | cttctcgcgcgcgc gcggccggtccctcctc |
### Molecular biology and peptide synthesis

Ca\textsubscript{\(1,2\)}, Ca\textsubscript{\(1,3\)}, Ca\textsubscript{\(1,4\_23\)}, Ca\textsubscript{\(2,1\)}, Ca\textsubscript{\(2,2\)}, Ca\textsubscript{\(2,3\)}, and Na\textsubscript{\(1,4\)} variants were unmodified from previously published constructs: Ca\textsubscript{\(1,2\)} (NM001136522) ([Wei et al., 1991](https://doi.org/10.1073/pnas.114728798)), Ca\textsubscript{\(1,2\)}-CaM\textsubscript{\(WT\)} ([Mori et al., 2004](https://doi.org/10.1073/pnas.114728798)), Ca\textsubscript{\(1,3\)}\textsubscript{\(S\)} (AF370009.1), Ca\textsubscript{\(1,3\)}\textsubscript{\(L\)} engineered from Ca\textsubscript{\(1,3\)}\textsubscript{\(S\)} and human long distal carboxyl tail (NM000718) ([Liu et al., 2010](https://doi.org/10.1073/pnas.114728798)), RNA-edited variant Ca\textsubscript{\(1,3\)}\textsubscript{\(MQDY\)} ([Bazzazi et al., 2013](https://doi.org/10.1073/pnas.114728798); [Huang et al., 2012](https://doi.org/10.1073/pnas.114728798)), Ca\textsubscript{\(1,4\)}\textsubscript{\(43\)}\textsuperscript{*} was gifted from Dr. Soong Tuck Wah (National University of Singapore), Ca\textsubscript{\(2,1\)}

| Reagent type (species) or resource | Designation          | Source or reference | Identifiers | Additional information |
|-----------------------------------|----------------------|---------------------|-------------|------------------------|
| Sequence-based reagent            | Ven-SH3-SH3 reverse primer | this paper          | tcgaaatcttagattat cagatctct gccaaggag |
| Sequence-based reagent            | Ven-U-motif forward primer | this paper          | ctttcgcggcgctaatgg tggac ccagttaatga |
| Sequence-based reagent            | Ven-U-motif reverse primer | this paper          | tcgaaatcttagattag tggaa cagttcatcag |
| Sequence-based reagent            | stac2 (KVD/AAA) sense | this paper          | cttctcgcgg ccagtttatga |
| Sequence-based reagent            | stac2 (KVD/AAA) antisense | this paper          | gcgctctagcagcagcagcagcagcag |
| Sequence-based reagent            | stac2 (PVY/AAA) sense | this paper          | ccagcggggaaggtggac gcgctctagcagcagcagcagcagcagcag |
| Sequence-based reagent            | stac2 (PVY/AAA) antisense | this paper          | cttctcgcgg ccagtttatga |
| Sequence-based reagent            | stac2 (ETL/AAA) sense | this paper          | gcgctctagcagcagcagcagcagcagcag |
| Sequence-based reagent            | stac2 (ETL/AAA) antisense | this paper          | ccagtttatagacgc ccagtttatagacgc |
| Sequence-based reagent            | stac2 (RYG/AAA) sense | this paper          | cttctcgcgg ccagtttatga |
| Sequence-based reagent            | stac2 (RYG/AAA) antisense | this paper          | ccagtttatagacgc ccagtttatagacgc |
| Sequence-based reagent            | stac2 (TSL/AAA) sense | this paper          | gcgctctagcagcagcagcagcagcagcag |
| Sequence-based reagent            | stac2 (TSL/AAA) antisense | this paper          | cttctcgcgg ccagtttatga |
| Sequence-based reagent            | stac2 (NRS/AAA) sense | this paper          | gcgctctagcagcagcagcagcagcagcag |
| Sequence-based reagent            | stac2 (NRS/AAA) antisense | this paper          | cttctcgcgg ccagtttatga |
| Sequence-based reagent            | stac2 (S/A) sense | this paper          | gcgctctagcagcagcagcagcagcagcag |
| Sequence-based reagent            | stac2 (S/A) antisense | this paper          | gcgctctagcagcagcagcagcagcagcag |

Software, algorithm PyMOL [http://www.pymol.org/](http://www.pymol.org/) RRID: SCR_000305
splice variant 37a(EFa) with 43°/44°/47° (Soong et al., 2002) was gifted from Dr. Terry Snutch (University of British Columbia), CaV2.2 (Jones et al., 1999), CaV2.3 (Mori et al., 2008), NaV1.4 (Trimmer et al., 1990). Stac variants were purchased from Origene: human stac1 mRNA transcript 1 (NP003140.1), mouse stac2 (NP666140.1), and human stac3 isoform 2 (NP659501.1). U-peptide was synthesized by Genscript (KVDPYETLRGYTSLALMNRS). Fhf variants were gifted from Dr. Gordon Tomaselli and Dr. Jeremy Nathans (Johns Hopkins University).

**Cell culture and transfection of HEK293 cells**

For whole-cell electrophysiology, single-channel electrophysiology, and immunohistochemistry, HEK293 cells (ATCC; mycoplasma tested negative) were cultured on glass coverslips in 10 cm dishes and transfected by a calcium phosphate method (Peterson et al., 1999) with the following amounts of DNA: 3 μg of SV40 T antigen to enhance expression, 2–8 μg of α1-subunit of Ca2+ or Na+ channel depending on expression, 8 μg from rat β2A (Perez-Reyes et al., 1992) (M80545), 8 μg from rat αδ (Tomlinson et al., 1993) (NM012919.2), and 8 μg of the stac1, stac2, or stac3 variants indicated.

For FRET two-hybrid experiments, cells were cultured on glass-bottom dishes and transfected with a standard polyethylenimine protocol (Lambert et al., 1996). Epifluorescence measurements were recorded 1–2 days after transfection.

**Adult guinea pig ventricular myocyte isolation**

Adult guinea pig ventricular myocytes (aGPVMs) were isolated from whole hearts of Hartley strain guinea pigs 3–4 weeks old (250–350 g). Guinea pigs were anesthetized via intraperitoneal injection with pentobarbital (35 mg/kg). Hearts were then excised, and single ventricular myocytes were isolated following a previously published protocol (Joshi-Mukherjee et al., 2013). Cells were plated on glass coverslips that were laminin (20 μg/mL) coated overnight at 4°C.

Immunohistochemistry aGPVMs plated on glass coverslips were first washed three times with cold PBS and then fixed in 3.7% paraformaldehyde (15710, Electron Microscopy Sciences) in PBS for 15 min. After washing three times with PBS, cells were permeabilized in cold 0.5% Triton X-100 in tris buffered saline (TBS) for 20 min and then blocked with 10% goat serum in PBS for 1 hr at room temperature. Cells were incubated overnight at 4°C in primary antibodies diluted in antibody diluent solution (IW-1000, IHC World): monoclonal anti-α-actinin (sarcomeric) antibody produced in mouse (1:300, A7811), anti-STAC (stac1) antibody [EPR12805]-N-terminal (1:100, ab181157) or anti-STAC2 (stac2) antibody-N-terminal (1:100, ab156080) produced in rabbit. Next day, cells were rinsed three times with 0.05% TWEEN20 (Sigma P9416) in TBS (TBS-T) for 5 min each. In the dark, cells were incubated with secondary antibodies (1:1000): goat anti-mouse IgG Alexa Fluor 488 (1:1000, A21121), goat anti-rabbit IgG Alexa Fluor 594 (1:1000, A21121), goat anti-rabbit IgG Alexa Fluor 594 (1:1000), and DAPI (1:10000) diluted in antibody solution for 45 min at room temperature and then washed three times with TBS-T for 5 min each. Stained cells were mounted with prolong gold mounting media (Invitrogen) on a microscope slide (Fischer Scientific).

Transfected HEK293 were immunostained following a similar protocol to that of aGPVM, but were not labelled with sarcomeric primary antibody and its respective secondary antibody.

Western blot aGPVMs and HEK293 cells were washed twice with PBS buffer. Cells were harvested with 1 mL 1x RIPA buffer (20–188, Sigma Aldrich) containing half a tablet of complete mini-EDTA-free protease inhibitor (11836170001, Sigma Aldrich) and incubated at 4°C for 30 min. Samples were centrifuged at 15,000 RPM for 15 min, and the pellet was discarded. Then, 2–5 μg of proteins in the supernatant were heated at 37°C for 30 min with 2x Laemmli sample buffer (S3401, Sigma Aldrich). Samples were loaded into 4–12% gradient gel (NP0335BOX, Invitrogen) with PageRuler plus pre-stained protein ladder (26619, Invitrogen) and run at 100 V for 2 hr at room temperature in running buffer: 1x NuPAGE MOPS SDS running buffer: 50 mM MOPS, 50 mM Tris base, 0.1% SDS, 1 mM EDTA, pH to 7.7. Proteins were transferred on ice from the gel to nitrocellulose membrane (10600003, GE Healthcare Life science) for 75 min at 10 V in transfer buffer: 24 mM Tris base, 192 mM glycine, 20% v/v methanol. Membrane was blocked with 5% (w/v) Blotting-Grade-Blocker (1706404, Bio-Rad) in 1x TRIS-buffered saline for 1 hr at 4°C. Primary antibody for stac2 (1:250) was added to the blocking buffer with 0.1% (v/v) Tween 20 (1706404, Bio-Rad) and incubated overnight at 4°C. Next day, the membrane was washed three times for 5 min each with TBS with 0.1% (v/v) Tween 20 (TBS-T). The secondary antibody (111-035-144, Jackson ImmunoResearch; 1:10,000) was
added to the blocking buffer with 0.1% (v/v) Tween 20 and incubated for 1 hr. The membrane was washed again three times for 5 min each with TBS-T. Finally, western blots were developed with SuperSignal West Pico Chemiluminescent Substrate (34580, ThermoFischer) and images were collected on an Alpha InnoTech FluorChem HD2 imaging system.

**Confocal optical imaging**

Images of immunostained tissue slices and cells were captured with either an Olympus Fluorview FV300 confocal laser scanning microscope or an LSM780 (Carl Zeiss, Oberkochen, Germany) confocal microscope. For the FV300, we used Fluoview software (Olympus) with a PlanApo 403 or 603 oil objective (NA 1.40, PLAPO60XO3; Olympus). Argon laser (488 nm) was used to excite Alexa Fluor 488 (green), and Helium Neon (HeNe) Green Laser was used to excite Alexa Fluor 594 (red). Olympus optical filters used were 442/515 nm excitation splitter (FV-FCV), 570 nm emission splitter (FV-570CH), BAS10 IF and BAS50RF for green emission channel, and 605 BP filter for red channel. Images were processed in ImageJ. Similar settings were used for the LSM780 setup.

**Whole-cell electrophysiology**

Whole-cell voltage-clamp recordings for HEK293 were collected at room temperature 1–2 days after transfection with Axopatch 200A (Axon Instruments). Glass pipettes (BF150-86-10, Sutter Instruments) were pulled with a horizontal puller (P-97; Sutter Instruments Company) and fire polished (Microforge, Narishige, Tokyo, Japan) to have 1–3 MΩ resistance. Recordings were low-pass filtered at 2 kHz and sampled at 10 kHz with P/B leak subtraction and 70% series resistance and capacitance compensation. For recordings of Ca$_{1.2}$ (Figure 1A–B, Figure 5I–K, Figure 6B), Ca$_{1.3s}$ (Figure 1C–D, Figure 3—figure supplement 1A–B and and G, Figure 7D–E, and Figure 8B–C), Ca$_{1.4s3}$ (Figure 1E–F), Ca$_{2.2}$ (Figure 1I–J), Ca$_{2.3/1.3}$ CI chimera (Figure 2E–F), Ca$_{1.3-CaM}$ (Figure 3A–B, Figure 3—figure supplement 1C–F, and Figure 5G–H), Ca$_{1.2-CaM}$ (Figure 2C–D, Figure 5A–F) and Ca$_{1.3\text{roxk}}$ (Figure 8D–E) exogenously expressed in HEK293 cells, the internal solution contained (in mM): CsMeSO$_3$, 114; CsCl, 5; MgCl$_2$, 1; MgATP, 4; HEPES, 10; BAPTA, 10; adjusted to 295 mOsm with CsMeSO$_3$ and pH 7.4 with CsOH. The external solution contained (in mM): TEA-MeSO$_3$, 140; HEPES, 10; CaCl$_2$, or BaCl$_2$ 40; adjusted to 300 mOsm with TEA-MeSO$_3$ and pH 7.4 with TEA-OH. For recordings of Ca$_{2.1}$ (Figure 1G–H) and Ca$_{2.3}$ (Figure 1K–L), the internal solution contained (in mM): CaMeSO$_3$, 135; CsCl, 5; MgCl$_2$, 1; MgATP, 4; HEPES, 10; EGTA, 1; adjusted to 295 mOsm with CsMeSO$_3$ and pH 7.4 with CsOH. The external solution contained (in mM): TEA-MeSO$_3$, 140; HEPES, 10; CaCl$_2$, or BaCl$_2$ 5; adjusted to 300 mOsm with TEA-MeSO$_3$ and pH 7.4 with TEA-OH. At a holding potential of ~80 mV, we used a family of test pulses from ~30 mV to +50 mV with repetition intervals of 20 s. Custom MATLAB (Mathworks) software (https://github.com/manubenjohny/WCDTY; copy archived at https://github.com/elifesciences-publications/WCDTY) was used to determine peak current and fraction of peak current remaining after either 300 ms ($t_{300}$) or 800 ms ($t_{800}$) of depolarization.

We incubated aGPVMs for 20–48 hr after isolation in 5 μM ryanodine for 5–10 min before we collected whole-cell recordings. The internal recording solution contained (in mM) CsMeSO$_3$, 114; CsCl, 5; MgCl$_2$, 1; MgATP, 4; HEPES, 10; BAPTA, 10; ryanodine, 0.005 adjusted to 295 mOsm with CsMeSO$_3$ and pH 7.4 with CsOH. Cells were sealed in Tyrodes solution, which contained (in mM): NaCl, 135; KCl, 5.4; CaCl$_2$, 1.8; MgCl$_2$, 0.33; NaH$_2$PO$_4$, 0.33; HEPES, 5; glucose, 5 (pH 7.4). For CDI measurements, external solutions containing (in mM): TEA-MeSO$_3$, 140; HEPES, 10; CaCl$_2$, or BaCl$_2$ 40; adjusted to 300 mOsm with TEA-MeSO$_3$ and pH 7.4 with TEA-OH were perfused. Welch’s T-test was used to verify statistical significance among the population data.

For CDI recordings, we determined required sample size based on power analysis. Based on historical estimates of normal variation in CDI/CDF measurements, we computed the sample size required such that type I and type II errors are 5% to be 3.5. Thus, we obtained at least four independent measurements for all electrophysiological experiments.

Current-clamp recordings of aGPVMs were performed on the same setup and were filtered at 5 kHz and sampled at 25 kHz. The internal solution contained (in mM): K glutamate, 130; KCl, 9; NaCl, 10; MgCl$_2$, 0.5; EGTA, 0.5, MgATP, 4; HEPES, 10; adjusted to pH 7.3 with KOH. The external solution contained (in mM): NaCl, 135; KCl, 5.4; CaCl$_2$, 1.8; MgCl$_2$, 0.33; NaH$_2$PO$_4$, 0.33; HEPES, 5; glucose, 5 (pH 7.4). The time from upstroke to 80% repolarization (APD$_{80}$) was measured with MATLAB.
(Mathworks) and used as a metric for comparing physiological output between peptide treated and untreated. For experiments with U-peptide, peptide was dissolved in ddH₂O to 2 mg/mL and then diluted to 500 μM in the appropriate internal solution.

**Single-channel electrophysiology**

Single-channel recordings were performed at room temperature using an on-cell configuration previously established in the laboratory (Tay et al., 2012) with the same setup as used for whole-cell electrophysiology. Glass pipettes were pulled and polished from ultra-thick-walled borosilicate glass (BF200–116–10, Sutter Instruments) and coated with sylgard to have 5–10 MΩ resistance. Recordings were filtered at 2–5 kHz. The pipette solution contained (in mM): TEA-MeSO₄, 140; HEPES, 10; BaCl₂, 40; adjusted to 300 mOsm with TEA-MeSO₄ and pH 7.4 with TEA-OH. The external solution contained (in mM): K glutamate, 132; KCl, 5; NaCl, 5; MgCl₂, 3; EGTA, 2; HEPES, 10; adjusted to 300 mOsm with glucose and pH 7.4 with KOH. Cell-attached single-channel currents were measured during 200 ms voltage ramps between −80 and +70 mV (portions between −50 and 40 mV displayed and analyzed) as previously described. For each patch, we recorded 80–150 sweeps with a repetition interval of 12 s. Patches were analyzed as follows: (1) The leak for each sweep was fit and subtracted from each trace. (2) The unitary current relation, i(V), was fit to the open-channel current level using the following equation:

\[
i(V) = -g \cdot (V - V_g) \cdot \exp(-(V - V_g) \cdot z \cdot F/(R \cdot T)) / (1 - \exp(-(V - V_g) \cdot z \cdot F/(R \cdot T)))
\]

where \(g\) is the single-channel conductance (−0.2 pA/mV), \(z\) is the apparent valence of permeation (−2.1), \(F\) is Faraday’s constant, \(R\) is the gas constant, and \(T\) is the temperature in degrees Kelvin (assumed room temperature). These parameters were held constant for all patches, except for slight variations in the voltage-shift parameter \(V_g\) ~ 35 mV, as detailed below. (3) All leak-subtracted traces for each patch were averaged (and divided by the number of channels in the patch) to yield an \(i-V\) relation for that patch. As slight variability in \(V_g\) was observed among patches, we calculated an average \(V_g\) for each construct, \(V_{g,AVE}\). The data from each patch were then shifted slightly in voltage by an amount \(\Delta V = V_{g,AVE} - V_g\), with \(\Delta V\) typically about ±5 mV. This maneuver allowed all patches for a given construct to share a common open-channel GHK relation. Thus shifted, the \(i-V\) relations obtained from different patches for each condition/construct were then averaged together. (4) \(P_0\) at each voltage was determined by dividing the average \(I\) (determined in step three above) into the open-channel GHK relation. Channel number was determined by the maximal number of overlapping opening events upon application of the channel agonist Bay K8644 (5 μM) at the end of each recording. For modal analysis, a dashed line discriminator was chosen to be the average single-trial \(P_0 = 0.075\) such that traces with average single-trial \(P_0 > 0.075\) were categorized as high \(P_0\) while the remaining traces were considered to be low \(P_0\).

**Quantitative calcium photo-uncaging**

All Ca²⁺-uncaging experiments were conducted on a Nikon TE2000 inverted microscope with a Plan Fluor Apo 40 X oil objective as previously described (Ben-Johny et al., 2014). Briefly, a classic Cairn UV flash photolysis system was used for Ca²⁺-uncaging with brief UV pulses of ~1.5 ms in duration powered by a capacitor bank of up to 4000 μF charged to 200–290V. For concurrent Ca²⁺ imaging, Fluo4FF and Alexa568 dyes were dialyzed via patch pipette and imaged using Argon laser excitation (514 nm). Background fluorescence for each cell was measured prior to pipette dialysis of dyes and subtracted subsequently. A field-stop aperture was used to isolate fluorescence from individual cells. Dual-color fluorescence emission was attained using a 545DCLP dichroic mirror, paired with a 545/40 BP filter for detecting Fluo4FF, and a 580LP filter for detecting Alexa568. Typically, uncaging experiments were conducted after ~2 min of dialysis of internal solution. Welch’s T-test was used to verify statistical significance between the population data.

For all Ca²⁺-uncaging experiments, the internal solution contained (in mM): CsMeSO₄, 120; CsCl, 5; HEPES (pH 7.4 with CsOH), 10; Fluo-4FF pentapotassium salt (Invitrogen), 0.01; Alexa 568 succinimidyl ester (Invitrogen), 0.0025; Citrate, 1; DM-Nitrophen EDTA (DMN) and CaCl₂ were adjusted to obtain the desired Ca²⁺ flash. Typically, for flashes in the range 0.5–2 μM, DMN, 1 mM; and CaCl₂, 0.7 mM. For the 2–8 μM range, DMN, 2 mM; and CaCl₂, 1.4 mM. For larger Ca²⁺ steps, DMN, 4 mM; and CaCl₂, 3.2 mM. As DMN can bind Mg²⁺, all experiments were conducted with 0 mM Mg²⁺.
internally. For all Na channel experiments, the bath solution contained (in mM): TEA-MeSO$_3$, 45; HEPES (pH 7.4), 10; NaCl, 100; at 300 mOsm, adjusted with TEA-MeSO$_3$.

**FRET-two-hybrid assay**

To collect a range of donor molecule ($D_{\text{free}}$) concentrations, HEK293 cells were transfected with combinations of DNA ratios. Cells were immersed in 2 mM Ca$^{2+}$ Tyrodes solution, which contained (in mM): NaCl, 138; KCl, 4; CaCl$_2$, 2; MgCl$_2$, 1; HEPES, 10; glucose, 10. Three-cube FRET fluorescence measurements were performed under resting Ca$^{2+}$ concentrations on an inverted fluorescence microscope. FRET efficiency ($E_A$ and $E_D$) was calculated for each cell (Erickson et al., 2001) and a binding curve, either $E_A = [D_{\text{free}}] / (K_{\text{d,EFF}} + [D_{\text{free}}]) \cdot E_{A,max}$ or $E_D = [A_{\text{free}}] / (K_{\text{d,EFF}} + [A_{\text{free}}])$, was fit to compute the effective dissociation constant ($K_{\text{d,EFF}}$).

**Acknowledgements**

We thank Deborah DeSilvestre, Rebeca Joca, and Travis Babola for assistance with immunohistochemistry, Hikeki Nakamura for confocal microscope training, Trudeau lab (Ashley Johnson and Sara Coddin) and Colecraft lab (Travis Morgenstern and Scott Kanner) for western blotting expertise. We are grateful for insightful discussions with the Calcium Signals Laboratory and Inoue Synthetic Biology Lab. Finally, we are indebted to the inspiration of Dr. David T Yue, who taught us to pursue science with a passion for the truth. This work was supported by grants from NINDS (DTY, IED, Ti), NIMH (DTY, MBJ), NHLBI (GFT) and NSF (JN).

**Additional information**

**Funding**

| Funder | Author |
|--------|--------|
| National Science Foundation | Jacqueline Niu |
| National Institute of Neurological Disorders and Stroke | Ivy E Dick, David T Yue, Takanari Inoue |
| National Institute of Mental Health | David T Yue, Manu Ben-Johny |
| National Heart, Lung, and Blood Institute | Gordon Tomaselli, Manu Ben-Johny |

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

**Author contributions**

Jacqueline Niu, Conceptualization, Data curation, Formal analysis, Investigation, Visualization, Methodology, Writing—original draft, Writing—review and editing; Ivy E Dick, Resources, Data curation, Funding acquisition, Writing—review and editing; Wanjun Yang, Resources; Moradeke A Bamgboye, Data curation; David T Yue, Funding acquisition; Gordon Tomaselli, Resources, Funding acquisition, Writing—review and editing; Takanari Inoue, Conceptualization, Supervision, Writing—review and editing; Manu Ben-Johny, Conceptualization, Data curation, Formal analysis, Investigation, Visualization, Writing—original draft, Writing—review and editing.

**Author ORCIDs**

Manu Ben-Johny [http://orcid.org/0000-0002-5645-0815](http://orcid.org/0000-0002-5645-0815)

**Ethics**

Animal experimentation: This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All of the animals were handled according to approved institutional animal care and use committee (IACUC) protocols of the Johns Hopkins University (GP15M172). The protocol was approved by the
Committee on the Ethics of Animal Experiments of the Johns Hopkins University. All surgery was performed under sodium pentobarbital anesthesia, and every effort was made to minimize suffering.

### Decision letter and Author response

**Decision letter** [https://doi.org/10.7554/eLife.35222.024](https://doi.org/10.7554/eLife.35222.024)

**Author response** [https://doi.org/10.7554/eLife.35222.025](https://doi.org/10.7554/eLife.35222.025)

### Additional files

#### Supplementary files

- Transparent reporting form
  
  DOI: [https://doi.org/10.7554/eLife.35222.022](https://doi.org/10.7554/eLife.35222.022)

### Data availability

All data generated or analysed during this study are included in the manuscript and supporting files.

### References

Adams PJ, Snutch TP. 2007. Calcium channelopathies: voltage-gated calcium channels. Sub-Cellular Biochemistry **45**, 215–251. [DOI: https://doi.org/10.1007/978-1-4020-6191-2_8](https://doi.org/10.1007/978-1-4020-6191-2_8), PMID: 18193639

Adams PJ, Rungta RL, Garcia E, van den Maagdenberg AM, MacVicar BA, Snutch TP. 2010. Contribution of calcium-dependent facilitation to synaptic plasticity revealed by migraine mutations in the P/Q-type calcium channel. *PNAS* **107**(18):18694–18699. [DOI: https://doi.org/10.1073/pnas.1009500107](https://doi.org/10.1073/pnas.1009500107), PMID: 20937883

Adams PJ, Ben-Johny M, Dick IE, Inoue T, Yue DT. 2014. Apocalmodulin itself promotes ion channel opening and Ca(2+) regulation. *Cell* **159**(6):608–622. [DOI: https://doi.org/10.1016/j.cell.2014.09.047](https://doi.org/10.1016/j.cell.2014.09.047), PMID: 25417111

Alseikhan BA, DeMaria CD, Colecraft HM, Yue DT. 2002. Engineered calmodulins reveal the unexpected eminence of Ca(2+) channel inactivation in controlling heart excitation. *PNAS* **99**(17):17185–17190. [DOI: https://doi.org/10.1073/pnas.262372999](https://doi.org/10.1073/pnas.262372999), PMID: 12486220

Babitch J. 1990. Channel hands. *Nature* **346**(6315):321–322. [DOI: https://doi.org/10.1038/346321b0](https://doi.org/10.1038/346321b0), PMID: 2165218

Bazzazi H, Ben Johny M, Adams PJ, Soong TW, Yue DT. 2013. Continuously tunable Ca(2+) regulation of RNA-edited CaV1.3 channels. *Cell Reports* **5**(5):367–377. [DOI: https://doi.org/10.1016/j.celrep.2013.09.006](https://doi.org/10.1016/j.celrep.2013.09.006), PMID: 24120865

Ben Johny M, Yang PS, Bazzazi H, Yue DT. 2013. Dynamic switching of calmodulin interactions underlies Ca2+ regulation of CaV1.3 channels. *Nature Communications* **4**(1):1717. [DOI: https://doi.org/10.1038/ncomms2727](https://doi.org/10.1038/ncomms2727), PMID: 23591884

Ben-Johny M, Yang PS, Niu J, Yang W, Joshi-Mukherjee R, Yue DT. 2014. Conservation of Ca2+/calmodulin regulation across na and Ca2+ channels. *Cell Reports* **15**(3):1657–1667. [DOI: https://doi.org/10.1016/j.celrep.2014.04.035](https://doi.org/10.1016/j.celrep.2014.04.035), PMID: 24949975

Ben-Johny M, Dick IE, Sang L, Limpiitikul WB, Kang PW, Niu J, Banerjee R, Yang W, Babich JS, Issa JB, Lee SR, Namkung H, Li J, Zhang M, Yang PS, Bazzazi H, Adams PJ, Joshi-Mukherjee R, Yue DN, Yue DT. 2015. Towards a unified theory of calmodulin regulation (Calmodulation) of Voltage-Gated calcium and sodium channels. *Current Molecular Pharmacology* **8**(2):188–205. [DOI: https://doi.org/10.2174/1874467208666150507110359](https://doi.org/10.2174/1874467208666150507110359), PMID: 25966888

Berridge MJ, Lipp P, Bootman MD. 2000. The versatility and universality of calcium signalling. *Nature Reviews Molecular Cell Biology* **1**(11):1–21. [DOI: https://doi.org/10.1038/35036035](https://doi.org/10.1038/35036035), PMID: 11413485

Bock G, Gebhart M, Scharinger A, Jangsaenghong W, Busquet P, Poggiani C, Sartori S, Mangoni ME, Sinnegger-Brauns MJ, Herzig S, Stiessnig J, Koschak A. 2011. Functional properties of a newly identified C-terminal splice variant of Cav1.3 L-type Ca2+ channels. *The Journal of Biological Chemistry* **286**(42):37236–37248. [DOI: https://doi.org/10.1074/jbc.M111.269951](https://doi.org/10.1074/jbc.M111.269951), PMID: 21998310

Bosch MK, Carrasquillo Y, Randsell JI, Kanakamedala A, Ornitz DM, Nerbonne JM. 2015. Intracellular FGF14 (iFGF14) is required for spontaneous and evoked firing in cerebellar purkinje neurons and for motor coordination and balance. *Journal of Neuroscience* **35**(44):6752–6769. [DOI: https://doi.org/10.1523/JNEUROSCI.3566-14.2015](https://doi.org/10.1523/JNEUROSCI.3566-14.2015), PMID: 25926453

Brusse E, de Koning I, Maat-Kievit A, Oostra BA, Heutink P, van Swieten JC. 2006. Spinocerebellar ataxia 1.2 and inhibit calcium-dependent inactivation. *PNAS* **103**(12):188–205. [DOI: https://doi.org/10.1073/pnas.1009500107](https://doi.org/10.1073/pnas.1009500107), PMID: 21998310

Campiglio M, Costé de Bagneaux P, Ortner NJ, Tuluc P, Van Petegem F, Flucher BE. 2018. STAC proteins associate to the IQ domain of CaV1.2 and inhibit calcium-dependent inactivation. *PNAS* **115**(31):1376–1381. [DOI: https://doi.org/10.1073/pnas.1715997115](https://doi.org/10.1073/pnas.1715997115), PMID: 29363593

Niu et al. eLife 2018;7:e35222. [DOI: https://doi.org/10.7554/eLife.35222](https://doi.org/10.7554/eLife.35222)
2013. Stac3 is a component of the excitation-contraction coupling machinery and mutated in native american myopathy. Nature Communications 4:1952. DOI: https://doi.org/10.1038/ncomms2952, PMID: 23736855
Hsu IU, Linsley JW, Varineau JE, Shafer OT, Kuwada JY. 2018. Dstac is required for normal circadian activity rhythms in Drosophila. Chronobiology International 35. DOI: https://doi.org/10.1080/07420528.2018.1454937, PMID: 29621409
Huang H, Tan BZ, Shen Y, Tao J, Jiang F, Sung YY, Ng CK, Raida M, Köhr G, Higuchi M, Fatemi-Shariatpanahi H, Harden B, Yue DT, Soong TW. 2012. RNA editing of the IQ domain in Cav1.3 channels modulates their Ca\(^{2+}\)-dependent inactivation. Neuron 73:304–316. DOI: https://doi.org/10.1016/j.neuron.2011.11.022, PMID: 22284185
Huttlin EL, Jedrychowski MP, Elias JE, Goswami T, Rad R, Beausoleil SA, Villén J, Haas W, Sowa ME, Gygi SP. 2010. A tissue-specific atlas of mouse protein phosphorylation and expression. Cell 143:1174–1189. DOI: https://doi.org/10.1016/j.cell.2010.12.001, PMID: 21183079
Jackman SL, Regehr WG. 2017. The mechanisms and functions of synaptic facilitation. Neuron 94:447–464. DOI: https://doi.org/10.1016/j.neuron.2017.02.047, PMID: 28472650
Jeong E, Choi HK, Park JH, Lee SY. 2018. STAC2 negatively regulates osteoclast formation by targeting the RANK signaling complex. Cell Death & Differentiation 25:1364–1374. DOI: https://doi.org/10.1038/s41418-017-0048-5, PMID: 29348675
 joiner ML, lee a. 2015. Voltage-Gated Cav1 channels in disorders of vision and hearing. Current Molecular Pharmacology 8:143–148. DOI: https://doi.org/10.2174/1874467208666150507104937, PMID: 25966955
Jones LP, DeMaria CD, Yue DT. 1999. N-type calcium channel inactivation probed by gating-current analysis. Biophysical Journal 76:2530–2552. DOI: https://doi.org/10.1016/S0006-3495(99)77407-2, PMID: 10233069
Joshu-Mukherjee R, Dick IE, Liu T, O’Rourke B, Yue DT, Tung L. 2013. Structural and functional plasticity in long-term cultures of adult ventricular myocytes. Journal of Molecular and Cellular Cardiology 65:76–87. DOI: https://doi.org/10.1016/j.yjmcc.2013.09.009, PMID: 24076394
Komatsu T, Kukelyansky I, McCaffery JM, Ueno T, Varela LC, Inoue T. 2010. Organelle-specific, rapid induction of molecular activities and membrane tethering. Nature Methods 7:206–208. DOI: https://doi.org/10.1038/nmeth.e1428, PMID: 20154678
Kraner SD, Novak KR, Wang Q, Peng J, Rich MM. 2012. Altered sodium channel-protein associations in critical illness myopathy. Skeletal Muscle 2:17. DOI: https://doi.org/10.1186/2044-5040-2-17, PMID: 22935229
Lambert RC, Maulet Y, Dupont JL, Mykita S, Craig P, Volsen S, Feltz A. 1996. Polyethylenimine-mediated DNA transfection of peripheral and central neurons in primary culture: probing Ca\(^{2+}\)-channel structure and function with antisense oligonucleotides. Molecular and Cellular Neuroscience 7:239–246. DOI: https://doi.org/10.1006/mcne.1996.0018, PMID: 8726106
Lee A, Scheuer T, Catterall WA. 2000. Ca\(^{2+}\)/calmodulin-dependent facilitation and inactivation of P/Q-type Ca\(^{2+}\) channels. The Journal of Neuroscience : The Official Journal of the Society for Neuroscience 20:6830–6838. PMID: 10995627
Lee A, Westenbroek RE, Haeseleer F, Palczewski K, Scheuer T, Catterall WA. 2018. Dstac is required for normal circadian activity rhythms in Drosophila. Chronobiology International 35. DOI: https://doi.org/10.1038/ncomms2952, PMID: 28003463
Lee SR, Adams PJ, Yue DT. 2015. Large Ca\(^{2+}\)-dependent facilitation of ca(V)/2.1 channels revealed by Ca\(^{2+}\)-photo-uncaging. The Journal of Physiology 593:2753–2778. DOI: https://doi.org/10.1113/JP270091, PMID: 25809476
Legha W, Gaillard S, Gascon E, Malapert P, Hocine M, Alonso S, Moqrich A. 2010. stac1 and stac2 genes define discrete and distinct subsets of dorsal root ganglia neurons. Gene Expression Patterns 10:368–375. DOI: https://doi.org/10.1016/j.gep.2010.08.003, PMID: 20736085
Li-fixed in the membrane of the spermatozoa without any modification to the spermatozoa. In a previous study, we demonstrated that expression of stac2 in rat testis was significantly increased in association with differentiation and maturation processes that are known to be crucial for sperm development. In this study, we aimed to investigate the biological and functional relevance of stac2 expression in the testis.

## Results

### Stac2 Expression in Rat Testis

To determine the expression pattern of stac2 in the rat testis, we performed in situ hybridization using stac2-specific probes. As shown in Figure 1A, stac2 expression was observed in the spermatogonia and spermatocytes, but not in the mature spermatozoa. In addition, stac2 expression was detected in the interstitial cells surrounding the seminiferous tubules. These findings suggest that stac2 may play a role in the development and differentiation of testicular cells.

### Functional Impact of Stac2 Depletion

To further investigate the role of stac2 in testicular function, we performed in vitro experiments using spermatogonia and spermatocytes isolated from stac2 knockout mice. As shown in Figure 1B, the number of cells in the late stages of spermatogenesis, such as spermatids and spermatozoa, was significantly reduced in the stac2 knockout samples compared to the wild-type samples. This finding suggests that stac2 is essential for the normal development and maturation of spermatogenic cells.

### Conclusion

In summary, our study demonstrates that stac2 is expressed in the developing testis and plays a crucial role in the differentiation and maturation of spermatogenic cells. Future studies will be required to determine the molecular mechanisms underlying the function of stac2 in testicular development.

---

[1] Pallone, F., & Chapple, E. (2012). The role of stac2 in testicular development. Biology of Reproduction, 87(2), 1–6.
[2] Li, J., & Zhang, Y. (2015). Stac2: a novel regulator of spermatogenesis. Reproductive Biology, 15(3), 151–157.
[3] Lee, S., & Chang, C. (2017). Stac2-mediated calcium signaling: new insights into testicular function. Frontiers in Physiology, 8, 1–10.

---

**References**

[1] Pallone, F., & Chapple, E. (2012). The role of stac2 in testicular development. Biology of Reproduction, 87(2), 1–6.
[2] Li, J., & Zhang, Y. (2015). Stac2: a novel regulator of spermatogenesis. Reproductive Biology, 15(3), 151–157.
[3] Lee, S., & Chang, C. (2017). Stac2-mediated calcium signaling: new insights into testicular function. Frontiers in Physiology, 8, 1–10.
et al
Niu. eLife 2018;7:e35222.
Research article
Polster A
Polster A
Pitt GS
Perez-Reyes E
Park DS
Pablo JL
Oz S
Ornitz DM
Nanou E
Mori MX
Minor DL
Fernández V, Monllau JM, Borrell V, Liner C, de la Iglesia N. 2015. Transcriptional profiling of hypoxic neural stem cells identifies Calcineurin-NFATc4 signaling as a major regulator of neural stem cell biology. Stem Cell Reports 5:157–165. DOI: https://doi.org/10.1016/j.stemcr.2015.06.008, PMID: 26235896
Mori MX, Erickson MG, Yue DT. 2004. Functional stoichiometry and local enrichment of calmodulin inactivating with Ca2+-bound CaV1.2 L-type Ca2+ channels. Science 304:426–435. DOI: https://doi.org/10.1126/science.1093940, PMID: 15087548
Mori MX, Vander Kooi CW, Leahy DJ, Yue DT. 2008. Crystal structure of the CaV2Q IQ domain in complex with Ca2+/calmodulin: high-resolution mechanistic implications for channel regulation by Ca2+. Structure 16:607–620. DOI: https://doi.org/10.1016/j.str.2008.01.011, PMID: 18400181
Nanou E, Sullivan JM, Scheuer T, Catterall WA. 2016. Calcium sensor regulation of the CaV2.1 Ca2+ channel contributes to short-term synaptic plasticity in hippocampal neurons. PNAS 113:1062–1067. DOI: https://doi.org/10.1073/pnas.1524636113, PMID: 2675594
Nelson BR, Wu F, Liu Y, Anderson DM, McAnally J, Lin W, Cannon SC, McAnally J, Lin W, Cannon SC, Bassel-Duby R, Olson EN. 2013. Skeletal muscle-specific T-tubule protein STAC3 mediates voltage-induced Ca2+ release and contractility. PNAS 110:11881–11886. DOI: https://doi.org/10.1073/pnas.1310571110, PMID: 23818578
Nguyen JT, Porter M, Amouei M, Miller WT, Zuckermann RN, Lim WA. 2000. Improving SH3 domain ligand selectivity using a non-natural scaffold. Chemistry & Biology 7:463–473. DOI: https://doi.org/10.1074/jcb.10093934
Niu J, Yang W, Yue DT, Inoue T, Ben-Johny M. 2018. Duplex signaling by CaM and STAC3 enhances Cav1.1 function and provides insights into congenital myopathy. The Journal of General Physiology 150:jgp.201812005. DOI: https://doi.org/10.1085/jgp.201812005, PMID: 29950399
Oliveria SP, Dittmer PJ, Youn DH, Dell’Acqua ML, Sather WA. 2012. Localized calcineurin confers Ca2+-dependent inactivation on neuronal L-type Ca2+ channels. Journal of Neuroscience 32:15328–15337. DOI: https://doi.org/10.1523/JNEUROSCI.2302-12.2012, PMID: 23115717
Ornitz DM, Itoh N. 2001. Fibroblast growth factors. Genome Biology 2:reviews3005.1.
Oz S, Benmocha A, Sasson Y, Sachyani D, Almagor L, Lee A, Hirsch JA, Dascal N. 2001. Fibroblast growth factors. The Journal of Biological Chemistry 276:32–37. DOI: https://doi.org/10.1074/jbc.M113.460949, PMID: 23500309
Pablo JL, Pitt GS. 2016. Fibroblast growth factor homologous factors: new roles in neuronal health and disease. The Neuroscientist : A Review Journal Bringing Neurobiology, Neurology and Psychiatry 22:19–25. DOI: https://doi.org/10.1177/1073858415622127, PMID: 25492945
Park DS, Shekhar A, Marra C, Lin X, Vasquez C, Solinas S, Kelley K, Morley G, Goldfarb M, Fishman GI. 2016. FhF2 gene deletion causes temperature-sensitive cardiac conduction failure. Nature Communications 7:12966. DOI: https://doi.org/10.1038/ncomms12966, PMID: 27701382
Perez-Reyes E, Castellano A, Kim HS, Bertrand P, Baggstrom E, Lacerda AE, Wei XY, Birnbaumer L. 1992. Cloning and expression of a cardiac/brain beta subunit of the L-type calcium channel. The Journal of Biological Chemistry 267:1792–1797. PMID: 1370480
Persechini A, Stemmer PM. 2002. Calmodulin is a limiting factor in the cell. Trends in Cardiovascular Medicine 12:32–37. DOI: https://doi.org/10.1016/S1070-1738(01)00144-X, PMID: 11796242
Peterson BZ, DeMaria CD, Adelman JP, Yue DT. 1999. Calmodulin is the Ca2+-sensor for Ca2+-dependent inactivation of L-type calcium channels. Neuron 22:549–558. DOI: https://doi.org/10.1016/S0896-6273(00)80709-6, PMID: 10197534
Pitt GS, Lee SY. 2016. Current view on regulation of voltage-gated sodium channels by calcium and auxiliary proteins. Protein Science 25:1573–1584. DOI: https://doi.org/10.1002/pro.2960, PMID: 27262167
Polster A, Perni S, Bichraoui H, Beam KG. 2015. Stac adaptor proteins regulate trafficking and function of muscle and neuronal L-type Ca2+ channels. PNAS 112:602–606. DOI: https://doi.org/10.1073/pnas.1423131112, PMID: 25548159
Polster A, Nelson BR, Olson EN, Beam KG. 2016. Stac3 has a direct role in skeletal muscle-type excitation-contraction coupling that is disrupted by a myopathy-causing mutation. PNAS 113:10986–10991. DOI: https://doi.org/10.1073/pnas.1612441113, PMID: 27621462
Polster A, Nelson BR, Papadopoulos S, Olson EN, Beam KG. 2018. Stat proteins associate with the critical domain for excitation-contraction coupling in the II-III loop of Cavα1.1. *The Journal of General Physiology* **150**: jgp.201711917. DOI: https://doi.org/10.1085/jgp.201711917, PMID: 29467163

Saimi Y, Kung C. 2002. Calmodulin as an ion channel subunit. *Annual Review of Physiology* **64**:289–311. DOI: https://doi.org/10.1146/annurev.physiol.64.103001.111649, PMID: 11826271

Satoh J, Nann Y, Yamamura T. 2006. Rapid identification of 14-3-3-binding proteins by protein microarray analysis. *Journal of Neuroscience Methods* **152**:278–288. DOI: https://doi.org/10.1016/j.jneumeth.2005.09.015, PMID: 16260042

Scharinger A, Eckrich S, Vandael DH, Schöning K, Koschak A, Hecker D, Kaur G, Lee A, Sah A, Bartsch D, Benedetti B, Lieb A, Schick B, Singewald N, Sinnegger-Brauns MJ, Carbone E, Engel J, Striessnig J. 2015. Cell-type-specific tuning of Cav1.3 Ca(2+)-channels by a C-terminal autoregulatory domain. *Frontiers in Cellular Neuroscience* **9**:309. DOI: https://doi.org/10.3389/fncel.2015.00309, PMID: 26379493

Schoorlemmer J, Goldfarb M. 2001. Fibroblast growth factor homologous factors are intracellular signaling proteins. *Current Biology* **11**:793–797. DOI: https://doi.org/10.1016/S0960-9822(00)00239-9, PMID: 11378392

Singh A, Gebhart M, Fritsch R, Sinnegger-Brauns MJ, Poggiani C, Hoda JC, Engel J, Romanin C, Striessnig J, Koschak A. 2008. Modulation of voltage- and Ca2+–dependent gating of Cav1.3 L-type calcium channels by alternative splicing of a C-terminal regulatory domain. *The Journal of Biological Chemistry* **283**:20733–20744. DOI: https://doi.org/10.1074/jbc.M802254200, PMID: 18482979

Smallwood PM, Munoz-Sanjuan I, Tong P, Macke JP, Hendry GH, Gilbert DJ, Copeland NG, Jenkins NA, Nathans J. 1996. Fibroblast growth factor (FGF) homologous factors: new members of the FGF family implicated in nervous system development. *PNAS* **93**:9850–9857. DOI: https://doi.org/10.1073/pnas.93.18.9850, PMID: 8794020

Soong TW, DeMaria CD, Alvana RS, Zweifel LS, Liang MC, Mittman S, Agnew WS, Yue DT. 2002. Systematic identification of splice variants in human P/Q-type channel alpha1(2.1) subunits: implications for current density and Ca2+-dependent inactivation. *The Journal of Neuroscience : The Official Journal of the Society for Neuroscience* **22**:10142–10152. DOI: https://doi.org/10.1523/JNEUROSCI.22-23.10142.2002, PMID: 12451115

Stiessnegg J, Bolz HJ, Koschak A. 2010. Channelopathies in Cav1.1, Cav1.3, and Cav1.4 voltage-gated L-type Ca2 + channels. *Pflügers Archiv - European Journal of Physiology* **460**:361–374. DOI: https://doi.org/10.1007/s00424-010-0800-x

Suzuki H, Kawai J, Taga C, Yaoi T, Hara A, Hirose K, Hayashizaki Y, Watanabe S. 1996. Stac, a novel neuron-specific protein with cysteine-rich and SH3 domains. *Proceedings of the National Academy of Sciences of the United States of America* **93**:2879–2882. DOI: https://doi.org/10.1073/pnas.93.05.2879, PMID: 8685369

Tan GM, Wang BZ, Thomas JR, Tay LH, Tan GM, Tan BZ, Suzuki H, Smallwood PM, Venetucci L, et al. 2011. Measuring Ca2+–dependent inactivation, Activation Potential, and Current Density. *The Journal of Biological Chemistry* **287**:832–847. DOI: https://doi.org/10.1074/jbc.M111.268722, PMID: 22069316

Tan BM, Lee A. 2017. Seeing the forest through the trees: towards a unified view on L-type Ca2+ channel sensor. *Current Opinion in Neuropharmacology* **32**:117–126. DOI: https://doi.org/10.1016/j.cnpool.2016.09.006, PMID: 28197066

Van Petegem F, Lobo PA, Ahern CA. 2012. Seeing the forest through the trees: towards a unified view on physiological calcium regulation of voltage-gated sodium channels. *Biophysical Journal* **103**:2243–2251. DOI: https://doi.org/10.1016/j.bpj.2012.10.020, PMID: 23283222

Venetucci L, Denegri M, Napolitano C, Priori SG. 2012. Inherited calcium channelopathies in the pathophysiology of arrhythmias. *Nature Reviews Cardiology* **9**:561–575. DOI: https://doi.org/10.1038/nrcardio.2012.93, PMID: 22733215

Wang HG, George MS, Kim J, Wang C, Pitt GS. 2007. Ca2+/calmodulin regulates trafficking of Ca(V)1.2 Ca2+ channels in cultured hippocampal neurons. *Journal of Neuroscience* **27**:9086–9093. DOI: https://doi.org/10.1523/JNEUROSCI.1720-07.2007, PMID: 17715345

Wang C, Hennessey JA, Kirkton RD, Wang C, Graham V, Puranam RS, Rosenberg PB, Bursac N, Pitt GS. 2011a. Fibroblast growth factor homologous factor 13 regulates Na+ channels and conduction velocity in murine hearts. *Circulation Research* **109**:775–782. DOI: https://doi.org/10.1161/CIRCRESAHA.111.247957, PMID: 21817159

Wang C, Wang C, Hoch EG, Pitt GS. 2011b. Identification of novel interaction sites that determine specificity between fibroblast growth factor homologous factors and voltage-gated sodium channels. *Journal of Biological Chemistry* **286**:24253–24263. DOI: https://doi.org/10.1074/jbc.M111.243903, PMID: 21566136
Wang C, Chung BC, Yan H, Lee SY, Pitt GS. 2012. Crystal structure of the ternary complex of a NaV C-terminal domain, a fibroblast growth factor homologous factor, and calmodulin. Structure 20:1167–1176. DOI: https://doi.org/10.1016/j.str.2012.05.001, PMID: 22705208

Wang C, Chung BC, Yan H, Wang HG, Lee SY, Pitt GS. 2014. Structural analyses of Ca²⁺/CaM interaction with NaV channel C-termini reveal mechanisms of calcium-dependent regulation. Nature Communications 5:4896. DOI: https://doi.org/10.1038/ncomms5896, PMID: 25232683

Wei XY, Perez-Reyes E, Lacerda AE, Schuster G, Brown AM, Birnbaumer L. 1991. Heterologous regulation of the cardiac Ca²⁺ channel alpha 1 subunit by skeletal muscle beta and gamma subunits. implications for the structure of cardiac L-type Ca²⁺ channels. The Journal of Biological Chemistry 266:21943–21947. PMID: 1718988

Wei EQ, Barnett AS, Pitt GS, Hennessey JA. 2011. Fibroblast growth factor homologous factors in the heart: a potential locus for cardiac arrhythmias. Trends in Cardiovascular Medicine 21:199–203. DOI: https://doi.org/10.1016/j.tcm.2012.05.010, PMID: 22867699

Wilhelm M, Schlegl J, Hahne H, Gholami AM, Lieberenz M, Savitski MM, Ziegler E, Reimer U, Wenschuh H, Mollenhauer M, Slotta-Hupenina J, Boese JH, Bantscheff M, Gerstmair A, et al. 2014. Mass-spectrometry-based draft of the human proteome. Nature 509:582–587. DOI: https://doi.org/10.1038/nature13319, PMID: 24870543

Wong King Yuen SM, Campiglio M, Tung CC, Flucher BE, Van Petegem F. 2017. Structural insights into binding of STAC proteins to voltage-gated calcium channels. PNAS 114:E9520–E9528. DOI: https://doi.org/10.1073/pnas.1708852114, PMID: 29078335

Wu J, Yan Z, Li Z, Qian X, Lu S, Dong M, Zhou Q, Yan N. 2016. Structure of the voltage-gated calcium channel Ca(v)1.1 at 3.6 Å resolution. Nature 537:191–196. DOI: https://doi.org/10.1038/nature19321, PMID: 27580036

Wu F, Quinonez M, DiFranco M, Cannon SC. 2018. Stac3 enhances expression of human Ca_{v}1.1 in Xenopus oocytes and reveals gating pore currents in HypoPP mutant channels. The Journal of General Physiology 475–489. DOI: https://doi.org/10.1085/jgp.201711962, PMID: 29386226

Yan H, Pablo JL, Wang C, Pitt GS. 2014. FGF14 modulates resurgent sodium current in mouse cerebellar Purkinje neurons. eLife 3:e04193. DOI: https://doi.org/10.7554/eLife.04193, PMID: 25269146

Yang PS, Alseikhan BA, Hiel H, Grant L, Mori MX, Yang W, Fuchs PA, Yue DT. 2006. Switching of Ca²⁺-dependent inactivation of Ca(v)1.3 channels by calcium binding proteins of auditory hair cells. Journal of Neuroscience 26:10677–10689. DOI: https://doi.org/10.1523/JNEUROSCI.3236-06.2006, PMID: 17050707

Yang PS, Johny MB, Yue DT. 2014. Allostery in Ca²⁺ channel modulation by calcium-binding proteins. Nature Chemical Biology 10:231–238. DOI: https://doi.org/10.1038/nchembio.1436

Zamponi GW. 2016. Targeting voltage-gated calcium channels in neurological and psychiatric diseases. Nature Reviews Drug Discovery 15:19–34. DOI: https://doi.org/10.1038/nrd.2015.5, PMID: 26542451

Zhang XD, Lieu DK, Chiamvimonvat N. 2015. Small-conductance Ca,Z+ -activated K+ channels and cardiac arrhythmias. Heart Rhythm 12:1845–1851. DOI: https://doi.org/10.1016/j.hrthm.2015.04.046, PMID: 25956967

Zimmer T, Surber R. 2008. SCNSA channelopathies–an update on mutations and mechanisms. Progress in Biophysics and Molecular Biology 98:120–136. DOI: https://doi.org/10.1016/j.pbiomolbio.2008.10.005, PMID: 19027780